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CHAPTER I 	  	  
INTRODUCTION AND LITERATURE REVIEW 	  	  
Introduction 
  
Since the 1980’s, techniques have rapidly developed and provided improved 
platforms for the generation of transgenic animals.  These techniques provide for the 
accurate manipulation of endogenous and exogenous genes.  For an animal to be 
considered transgenic (genetically modified), its genome must be altered to contain 
exogenous DNA or an applied modification to the endogenous genome.  The term 
“transgenic” was first described by Gordon and Ruddle (1981) in experiments to generate 
genetically modified mice.  The relative ease of transgenesis and the available techniques 
used to perform genetic engineering has allowed for its successful use.  However, while 
the manipulation of a genome has become more efficient, recent efforts have been made 
to control for the site-specific integration of transgenes. 
Performing genetic modifications without control for the site of integration can 
result in expression variation, both level and/or cell variegation.  In an attempt to 
overcome position effects related to transgene expression, investigators have tried to 
optimize the transgene design as well as the site of integration.  With the recent discovery 
and development of programmable nucleases, the scenario is likely to change 
dramatically and the generation of transgenic animals by using random methods of 
	   2 
integration may become obsolete.  The ability to remove the uncertainty surrounding 
random insertion of transgenes will allow for planning of transgene insertion into pre-
selected genomic sites, such as potential “safe-harbors” within the hosts’ genome.  
 
 
Brief History of Pig Transgenesis 
 
 Animal models are commonly used for the studies of science (genetics, 
physiology, diseases), agriculture (feed efficiency, growth rate, disease resistance), and 
health (xenotransplantation, pharmaceuticals).  Due to their short generation interval, size, 
and housing cost, rodents, Drosophila melanogaster, and Caenorhabditis elegans are the 
favored models used for the study of health and science.  However, there are distinct 
anatomical and physiological differences between these models and humans that could 
inhibit the direct application of gained knowledge to human medicine.  Pigs are seen as a 
potential model in which direct application of gained knowledge can be applied to 
humans.  In many respects pigs are similar to humans physiologically and anatomically, 
dependent upon age and/or breed, thus can serve as important models for the study of 
human health and science (Mc & Tribe, 1954). 
 There are several disadvantages of using pigs as models, with the major being the 
relative difficulty of generating genetically modified pigs when compared to other 
species.  The first transgenic pig was produced by pronuclear microinjection of a human 
growth hormone gene (Hammer et al., 1985).  Pronuclear microinjection is a method that 
delivers exogenous DNA to the male and/or female pronucleus of a newly fertilized 
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oocyte.  This technique is used to facilitate gain-of-function transgenesis by the 
incorporation of exogenous DNA into the host genome.  There are however, several 
disadvantages/limitations to this technology; such as random integration, mosaicism, and 
low efficiency (~0.5 – 10% of offspring are transgenic) (Pursel & Rexroad, 1993; Clark 
et al., 1994). 
 In contrast to pronuclear injection where the resulting modifications are random 
insertions of exogenous DNA, sometimes a more detailed and precise modification is 
required.  These precise modifications can be achieved with gene targeting via 
homologous recombination.  In 1981, two groups derived pluripotent cells from the inner 
cell mass of mouse blastocysts (Evans & Kaufman, 1981; Martin, 1981).  The established 
cells became known as embryonic stem (ES) cells.  ES cells have the unique ability to 
grow as immortal cells and maintain both a normal karyotype and an undifferentiated 
state.  However, given the proper stimulus, ES cells can be manipulated in vitro to 
develop into various cells types.  ES cells were first used for early development and cell 
lineage studies until 1984 when Bradley et al. (1984) demonstrated the ability of ES cells 
to transmit to the germ line of chimeric mice produced from the injection of ES cells into 
recipient blastocysts.  Due to these characteristics, gene targeting techniques were 
developed and the efficacy of gene targeting was initially tested and demonstrated in ES 
cells.  After ES cells have been genetically modified, the ES cells are injected into the 
blastocoel cavity of a blastocyst stage embryo.  The ES cells will incorporate amongst the 
other cells inside the recipient blastocyst and contribute to all cell lineages, generating a 
chimeric animal.  Since, ES cells can contribute to the germ cell population, the breeding 
of founder animals can lead to transmission of new genes through the germ line.  
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However, germline transmission does not always occur, thus is an obvious disadvantage 
of this technique.  Another major disadvantage is that despite considerable efforts, ES 
cells capable of contributing to the germline of any species, other than rodents, have not 
been isolated (Notarianni et al., 1991; Stice et al., 1996).  Even though authentic ES cells 
have not been isolated from pigs, the genetic manipulation technologies and techniques 
developed in the mouse (Capecchi, 1989) are transferrable to pigs. 
In the absence of non-murine ES cells, transgenic animal technology (excluding 
rodents) was hindered in other species.  However, in 1996 Dolly the sheep was produced 
through somatic cell nuclear transfer (SCNT) (Campbell et al., 1996; Wilmut et al., 1997).  
Dolly was a viable lamb that resulted from the transfer of a somatic cell to an enucleated 
oocyte.  SCNT involves the addition of a somatic cell into the perivitelline space of an 
enucleated oocyte.  An electrical pulse was used to fuse the cell to the oocyte.  Following 
fusion, the oocyte was activated by either electrical or chemical means to start embryo 
development.  The embryo was then transferred into a surrogate; where the time of the 
transfer is in coordination with embryo development and the cycle of surrogate recipient 
(Campbell et al., 1996; Schnieke et al., 1997; Cibelli et al., 1998; Baguisi et al., 1999; 
McCreath et al., 2000; Polejaeva et al., 2000; Denning et al., 2001).  The significance of 
SCNT is that for the first time, Campbell et al. (1996) demonstrated that NT could reset 
the program of a cell and generate viable offspring.  This opened up the possibility of 
bypassing the ES cell technology.  SCNT was a major scientific discovery that allowed 
genetic modifications to be conducted on somatic cells and subsequently used to produce 
transgenic animals.  There are many advantages of cloning through SCNT over that of 
pronuclear injection and producing ES cell chimeras.  The most obvious is that every cell 
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of the resulting transgenic animal contains the transgene; this reduces the time involved 
in analysis and production of a transgenic animal, which is a major advantage when 
working with a species such as the pig where the interval to return offspring from the 
birth of the founder animals is 12 – 16 months.  However, there are also many pitfalls 
associated with this technology.  In particular, efficiency of cloning in livestock species is 
low due to high embryo loss, developmental problems, and even post-parturition 
mortality. 
 In 1997, the first transgenic livestock produced by SCNT was a transgenic sheep 
that expressed human clotting factor IX in its milk (Schnieke et al., 1997).  In 2000, 
SCNT was combined with gene targeting in sheep.  The resulting animals contained a 
targeted knock-in of a therapeutic transgene into the ovine alpha-I procollagen locus 
(McCreath et al., 2000).  The first reports of pigs with targeted genetic modifications to 
knockout an endogenous gene were published in 2002 (Dai et al., 2002; Lai et al., 2002).  
The resulting pigs lacked one functional copy of a gene encoding for alpha1,3-galactosyl 
residue on the surface of pig cells.  These pigs were designed for potential use in pig-to-
human xenotransplantation.   
 Reports about other transgenic pigs with specific genetic modifications for 
various purposes have followed.  For the study of human diseases, genetically modified 
pigs have been generated to model cystic fibrosis (Rogers et al., 2008).  These pigs 
possessed a synonymous mutation of the cystic fibrosis transmembrane conductance 
receptor gene.  As the mouse model does not recapitulate the human phenotypic defects, 
these pigs are a better model to aid in the discovery of a cure for the disease (Grubb & 
Boucher, 1999).  For the study of animal agriculture, pigs have been produced that 
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express polyunsaturated fatty acids (Saeki et al., 2004; Lai et al., 2006).  These pigs 
contain fatty acid desaturases, enzymes that are normally not expressed in mammals, and 
as a result have higher polyunsaturated fatty acid content in their bodies.  The meat from 
these pigs would be considered healthier as meats that are high in polyunsaturated fatty 
acids are recognized as having health benefits in reducing the incidences of coronary 
artery disease and diabetes (Dyerberg & Bang, 1979; Kinsella et al., 1990).  There have 
even been reports of pigs that can be used to produce recombinant proteins important for 
human medicine, such as erythropoietin – a glycoprotein used to treat erythropoietin-
related anemia (Park et al., 2006).   
 It is easy to recognize that genetically modified pigs can be valuable in many 
fields.  However, the number of transgenic pigs that have been produced, in comparison 
to mice, is limited due to the difficulties associated with their production.  Thus advances 
in transgenic pig production are needed to better utilize pigs as a model organism. 
 
 
 
Gene Targeting 
 
 In 1980, the first description of a “transgenic” animal produced by injected 
foreign DNA into the pronuclei of mouse zygotes was reported (Gordon & Ruddle, 1981).  
This was followed by the generation of the first transgenic livestock in 1985 (Hammer et 
al., 1985).  A major limitation in the generation of the first transgenic animals was 
random integration of exogenous DNA that resulted in unpredictable transgene 
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expression (Clark et al., 1994; Bonifer et al., 1996).  In an attempt to overcome these 
position effects and to direct specific genetic modifications, gene targeting was developed.  
In addition, several applications can utilize gene targeting: 1) the precise integration of a 
functional foreign gene into a chosen genomic region (gene knock-in), 2) the replacement 
of an allele by another allele (point mutagenesis), and 3) the replacement of a gene by a 
nonfunctional DNA sequence leading to the inactivation of the targeted gene (gene 
knockout).   
Gene targeting was initially discovered in mammalian cells after integration of 
plasmid DNA in the cells occurred (Folger et al., 1982).  Shortly thereafter, another group 
reported gene targeting of an endogenous gene in mammalian cultured cells; thus proving 
gene targeting is possible (Smithies et al., 1985).  It was later determined that mammalian 
cells contain an enzymatic machinery that mediates homologous recombination (HR).  
HR is the process that mediates gene targeting. 
 Homologous recombination is the exchange of homologous sequence between 
two DNA molecules.  This is a natural phenomenon during meiosis and mitosis when the 
exchange of genetic information between complementary DNA strands occurs.  HR was 
first identified in a mutant Escherichia coli strain (Clark & Margulies, 1965).  HR is 
present in many species and is involved in many cellular mechanisms (Heyer et al., 2010).  
HR is a critical activity that is involved with the exchange of information between 
maternal and paternal alleles to provide genetic diversity.  During mitosis, HR’s main 
function is to provide genome stability and repair damaged DNA during replication or 
damage incurred from exogenous stress (Takata et al., 1998). 
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 Even though mammalian cells have the cellular machinery to direct exogenous 
DNA into an endogenous target site, it is known that the exogenous DNA is also inserted 
into random sites within the host genome by non-homologous recombination.  It has been 
estimated that random integration occurs approximately 30,000 – 40,000 times more 
frequently than HR (Brinster et al., 1989; Hasty, Rivera-Perez, Chang, et al., 1991) and 
the efficiency of gene targeting is approximately 1×10-6 (Reid et al., 1991; Templeton et 
al., 1997).  Gene targeting is an extremely rare event, due in part to the need for a double 
strand break (DSB) where the desired exogenous DNA is to be inserted.  
 Strategies to increase gene targeting efficiency begin with the construction of a 
gene targeting vector.  A targeting vector is designed to have homologous arms that flank 
an extrinsic sequence (transgene, subtle mutation).  Generally, the targeting arms range in 
length of 1 – 6 kb and the length of contiguous sequence identity has been shown to be a 
major determinant in HR efficiency (Waldman & Liskay, 1988).  Additionally the 
efficiency of HR is correlated with the length of homology; therefore as homology length 
increases so does gene targeting efficiency.  It should also be noted that successful HR 
has been reported by using less than 0.5 kb of homology per arm (Hasty, Rivera-Perez, & 
Bradley, 1991). 
 Additional approaches have been developed to enhance for the isolation of 
targeted clones; positive selection, negative selection, and trapping endogenous elements.  
Positive selection utilizes a marker, such as a drug resistant gene to facilitate the isolation 
of targeting events.  The addition of a positive selection marker provides enrichment 
towards isolating cells that contain the targeting construct, allowing only cells that 
express the marker to grow under selection.  However, a standard positive selection 
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cassette does not differentiate a targeting event from a random integrant.  Another 
enrichment strategy uses the addition of a negative selectable marker, such as Thymidine 
Kinase or Diphtheria Toxin (Yagi et al., 1990).  The negative marker flanks one of the 
homology arms and provides selection against random integrants by inducing death of 
such cells.  Since the negative marker does not integrate during homologous 
recombination, cells that have undergone a targeting event remain alive.  The 
simultaneous use of both positive and negative selection strategies is referred to as 
positive-negative selection (Mansour et al., 1988).   
Some other strategies attempt to “trap” functions that are provided by the 
endogenous gene but are omitted from the targeting vector (promoter trap, poly (A) trap, 
etc.).  In the strategy of a promoter trap, the selectable marker gene will only be 
expressed if inserted in the correct orientation relative to the promoter of an endogenous 
gene, thereby substantially reducing the number of random integrations recovered after 
positive selection (Doetschman et al., 1988).  This strategy has yielded an estimated 
enrichment of 20 – 120 fold when compared to a selectable marker that contains its own 
promoter.  However, there are some potential problems with this technique.  There is still 
the possibility that the targeting construct will randomly insert into another active gene; 
therefore the selectable marker is still expressed.  In addition, only actively transcribed 
genes are available for gene targeting by using this method.  To allow for the translation 
of a selectable marker without a promoter, an internal ribosomal entry site (IRES) can be 
inserted upstream of the selectable marker.  An IRES is found in picornaviruses, such as 
encephalomyocarditis virus and foot-and-mouth disease virus and is responsible for the 
initiation of mRNA translation (Macejak & Sarnow, 1991).  In the context of a transgene, 
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an IRES is located 5' of the initiation codon and initiates translation of the subsequent 
coding sequence following the IRES sequence.   
The poly(A) trap enrichment can be useful in targeting non-expressing genes as 
this method relies on the integration site providing the poly(A) signal for the positive 
selectable marker gene (Thomas & Capecchi, 1987).  This strategy has yielded an 
increase in enrichment of 2 – 5 fold.  Due to the limited increase in efficiency, this 
enrichment strategy is not used as frequently as other enrichment strategies (Jasin & Berg, 
1988; Waldman & Liskay, 1988; Sedivy & Sharp, 1989).   Enrichment strategies can be 
combined, but the combination does not always further increase enrichment (Beaton et al., 
2013).  Although various strategies have been developed to screen for cells with targeted 
insertion of exogenous DNA, an effective method is still needed to promote gene 
targeting. 
 
 
 
Programmable Nucleases 
 
Given that gene targeting is an extremely rare event, several groups have tried 
various strategies to increase the efficiency of HR.  The most promising of those 
strategies was through the use of “molecular scissors”.  The basic concept is that an 
endonuclease can be site-specifically directed and produce a DSB in the targeted DNA 
location.  This was first shown using the yeast I-SceI meganuclease, where it was 
demonstrated that DSBs within the targeted region of the target gene is compatible with 
efficient HR (Rouet et al., 1994).  In various species, the rate of HR has increased to 1 – 
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18% events per mammalian cell when targeted a DSB was introduced when compared to 
0.000001% (a one in a million) HR events without the use of any molecular scissor (Smih 
et al., 1995). 
Currently, there are three major meganuclease methodologies that are currently 
and successfully being used to make genetic modifications.  These approaches are zinc-
finger nucleases (ZFNs) (Hauschild et al., 2011; Whyte et al., 2011; Yang et al., 2011), 
transcription activator-like effector nucleases (TALENs) (Carlson et al., 2012; Tan et al., 
2013; Lee et al., 2014), and CRISPR/Cas9 (Tan et al., 2013; Whitworth et al., 2014).  
ZFNs and TALENs both consist of a non-specific cleavage domain of FokI endonuclease 
with a zinc finger domain (specific DNA binding zinc fingers) or transcription activator-
like effectors (TALEs) specific to a target DNA sequence, respectively.  The 
CRISPR/Cas9 system is a nuclease guided by a short RNA that pairs with the target DNA.  
Once paired the Cas9 enzyme cleaves both strands of DNA creating a DSB (Jinek et al., 
2012).  All of these approaches induce DSBs at predetermined locations within the host 
genome.  This genomic breakage can be repaired imprecisely by non-homologous end 
joining (NHEJ) to generate random mutations or can be repaired precisely when 
exogenous donor DNA is template for HR (Gaj et al., 2013). 
 
 
Recombinase-Mediated Exchange 
 
Site-specific recombination systems mediate control of a variety of biological 
functions by catalyzing precise excision, inversion, or integration of defined DNA 
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fragments.  Due to the accuracy of recombination and relative simplicity of use, site-
specific recombination systems have been the focus of studies in plants, flies, and mice.  
These systems are generally denoted by the name of recombinase protein, followed by 
the name of the DNA recognition sequence.  Two of the most widely used site-specific 
recombination systems for eukaryotic applications are Cre/loxP from bacteriophage P1 
(Sternberg et al., 1981) and FLP-FRT from the 2 µ plasmid of Saccharomyces cerevisiae 
(Andrews et al., 1985).  Both of these recombinases belong to the tyrosine recombinase 
family and can be used to promote DNA integration events, but deletion events are 
kinetically favored and thus are commonly used for the deletion characteristic in many 
genetic engineering strategies.  In contrast, the serine recombinase family is solely 
devoted to DNA integration.  The most widely used member of this family is PhiC31 
(Thorpe & Smith, 1998).   
All three of these systems are characterized by their ability to function 
independently of DNA topology, through the interaction of a single recombinase with a 
pair of specific recognition sites.  In the case of loxP and FRT, the recombination site 
required on both DNA substrates is a 34 bp palindromic sequence comprised of 13 bp 
inverted repeats surrounded by an 8 bp asymmetric spacer region that confers 
directionality to the site and thus to the recombination reaction.  In contrast to identical 
recombination target substrates of the Cre-loxP and FLP-FRT systems, the PhiC31 
system recognizes non-identical attB (attachment Bacteria) and attP (attachment Phage) 
sequences and upon recombination generates two new sites denoted attL (att Left) and 
attR (att Right).  The newly generated sites are chimeric compositions of attP and attB 
sites.  Thus, attP and attB are destroyed upon recombination and cannot further serve as 
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substrates for the PhiC31 recombinase.  This type of specificity and unidirectionality 
allow for the PhiC31 system to be used as a tool for site-specific genome manipulations. 
Orientation of the loxP and/or FRT (loxP / FRT) sites determines the outcome of 
the recombination event in that the loxP / FRT sites oriented in the same direction on a 
chromosomal segment result in a cyclization; excision of one of the loxP / FRT sites and 
the sequence that lies in between the two sites.  Alternatively, two loxP / FRT sites 
oriented in opposite directions on a chromosomal segment result in an inversion of the 
intervening segment upon Cre / FLP-mediated recombination, respectively.  loxP / FRT 
sites in the same orientation are commonly used to generate removable gene disruption 
cassettes as well as deletions of chromosomal segments for analysis of gene function in a 
variety of organisms by gene-targeting methods to flank a gene or promoter elements 
with loxP / FRT sites (Sauer, 1987; Orban et al., 1992).  Since the gene encoding Cre 
and/or FLP recombinase, is not found in eukaryotes, engineered regulation of transgenic 
expression enables this system to delete sequences flanked by loxP / FRT sites, in an 
inducible as well as temporal- and tissue-specific manner.  In traditional gene targeting, a 
selectable marker remains in the targeted genome.  Site-specific recombination systems 
have been used to remove the selectable marker after an insertion event (Meyers et al., 
1998; Nagy et al., 1998).  The removal of a selectable marker is advantageous for two 
main reasons: 1) to circumvent any concerns that the presence of a selectable marker 
cassette may affect the expression of neighboring genes (Fiering et al., 1995), and 2) to 
“recycle” the original targeting vector (or the marker gene contained within it) to create a 
homozygous KO cell line.  In the case of Cre-loxP mediated deletion, the vector must be 
designed to include loxP sites that flank the selectable marker.   
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Utilization of a recombinase to stack genes as part of mammalian transgenesis 
could improve the ability to predict transgene expression as well as provide a means to 
link multiple transgenes.  This strategy requires that a chromosomal location be known to 
facilitate appropriate transgene expression levels for the transgene promoter of interest 
and that the target locus is “tagged” with an appropriate recombination sequence.  The 
PhiC31 integrase for example is a site-specific recombinase that normally performs 
precise, unidirectional recombination between two aforementioned attachment sites.  
Keravala and Calos (2008) demonstrated that when an attP site is pre-integrated into a 
mammalian chromosome it can serve as a target for integration of an introduced plasmid 
carrying an attB site.  Once recombination occurs, it leads to the precise integration of the 
attB plasmid into the chromosome at the attP site and will provide a high net efficiency 
of net integration.  Previous work by the Calos lab showed that the PhiC31 integrase 
works in humans, mice, and Drosophila (Groth et al., 2000; Olivares et al., 2001; 
Thyagarajan et al., 2001; Groth et al., 2004; Bertoni et al., 2006; Chalberg et al., 2006; 
Fish et al., 2007).  In principle, site-specific integration can be used to deliver a second 
transgene next to a previously inserted transgene; therefore genetically linking the 
transgenes.  To enable this process the first transgene would have to include an 
appropriate recombination site and retain the ability to add additional transgenes, and 
each new transgene must contain an appropriate recombination site.   
 
 
 
 
	   15 
Transgene Design 
 
 Animal transgenesis is used to create models for multiple purposes: 1) the study 
of gene function, 2) modify organs and tissues for xenotransplantation, 3) prepare 
recombinant proteins, and 4) improve animal production characteristics (Wheeler & 
Walters, 2001).  In general, the addition of genes is required to yield the desired 
phenotype.  This requires the ability to control transgene expression.  However, gene 
targeting and targeted mutation, which includes gene knockout and gene knock-in, is 
becoming more common as techniques to provide the desired phenotype.  From the 
earliest gene transfer studies; it became apparent that expression of transgenes from 
randomly integrated transgenes was variable between different lines of transgenic 
animals.  The variability had an effect on the desired level, location, and/or timing of 
expression.   
 In general, a transgene expression cassette is designed to contain all of the 
necessary components of a functional gene.  The minimum requirements to construct a 
transgene include three main components: 1) a promoter, with the purpose to facilitate the 
transcription of the transgene, 2) a region of DNA that encodes the desired gene product, 
with the most common form being generated from cDNA (complementary DNA that has 
been synthesized from messenger RNA), and 3) a termination signal, which terminates 
translation of the transgene.  These three components are the minimal requirements for a 
transgene.   
Beyond the minimum requirements of a transgene several approaches have been 
explored to improve the expression of transgenes, such as to: add known regulatory 
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elements that favor transcription; use genomic DNA fragments expected/known to 
contain most of the transcriptional regulatory elements; target an endogenous gene 
known to favor the desired transgene expression.  Included within these major 
approaches, are some “rules” in regard to obtaining efficient and desired transgene 
expression.  These rules include and/or are related to: the addition of introns, 
optimization of the transcribed region, addition of insulators, and control of transgene 
expression by exogenous inducers.   
The inclusion of introns in the transgene construct has been shown to increase the 
levels of transgene expression dramatically (Brinster et al., 1988).  The mechanism for 
the increased expression is not entirely known, but it has been proposed that at least one 
intron is required to favor the transfer of mRNA to the cytoplasm and/or introns of many 
genes contain binding sites for transcription factors and thus aid in transgene expression.  
It appears that the location of intron(s) is desired before the coding region, but it should 
also be noted that the addition of intron(s), no matter the location, is advantageous 
(Chang et al., 2007).  The structure of the gene or coding region can also have an effect 
on gene expression; there have been several studies to demonstrate that higher levels of 
gene expression can be obtained with genomic DNA than that of those obtained with 
cDNA (Brinster et al., 1988).  This makes sense, as the transcribed regions of genes 
contain multiple signals that control mRNA translation and stability (Beelman & Parker, 
1995; Chkheidze et al., 1999; Knirsch & Clerch, 2000).  Additionally, the introns 
included in the transgene need not necessarily be derived from the gene of interest as 
expression from transgenes can be subsequently enhanced by the inclusion of 
heterologous introns in the transgene cassette (Palmiter et al., 1991). 
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It should also be noted that in addition to the transgene cassette design, some 
integration sites may partially or completely suppress transgene expression, whereas 
other sites may actually facilitate expression (Clark et al., 1994; Bonifer et al., 1996).  In 
addition to mis-regulated expression, in some cases the loss in function of an endogenous 
gene occurs.  In this instance, the sites of integration could knockdown or KO an 
important regulatory gene that is required for development, for example, mice resulting in 
male sterility (Magram & Bishop, 1991; Walters et al., 2009).  In addition, multiple 
copies of the transgene, even in tandem, may be less efficiently transcribed than if a 
single copy is inserted (Garrick et al., 1998).  It should also be noted that transgene 
expression is not necessarily transferrable from cultured cells to transgenic animals.  In 
some instances, transgenes are expressed in cultured cells, but not in the transgenic 
animals.  Dependent upon the regulatory elements (i.e., cell specificity), the reverse is 
generally not true, an active transgene that is expressed in an animal is generally 
expressed in cultured cells. 
 
 
 
Dissertation Objectives 
 
The overall objective of this dissertation is to develop an efficient method(s) to 
sequentially stack multiple transgenes into a single target site, inherently genetically 
linking multiple modifications.  The main objectives addressed herein are in relation to 
swine genetic engineering, but could be applied to other species, and are as follows: 1) to 
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evaluate the PhiC31 Recombinase system as a strategy to sequentially stack transgenes 
into a preselected attB site, 2) to evaluate the effect of donor DNA homology length on 
the outcome of nuclease-mediated gene targeting, 3) to evaluate the clustered regularly 
interspaced short palindromic repeats (CRISPR)/ CRISPR associated protein 9 (Cas9) 
(CRISPR/Cas9) system as a tool to mediate gene stacking and gene targeting, and 4) to 
examine the functionality and expression of transgenes in a multi-transgenic pig.  	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CHAPTER II 
 
COMPOUND TRANSGENICS:  
RECOMBINASE-MEDIATED GENE STACKING 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reference: Beaton BP and Wells KD. (2014)  Compound Transgenics: 
Recombinase-Mediated Gene Stacking.  In CA Pinker (Ed.), Transgenic 
Animal Technology 3rd Edition (p.565 – 578). Waltham, MA: Elsevier. 
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INTRODUCTION 	  
Genetic engineering technologies have matured to a point where there are no 
technological barriers that differentiate mammalian models, from mice to pigs, in regard 
to the types or extent of genetic modifications that can be accomplished.  Due to the 
physiological and anatomical similarities between pigs and humans, it is likely that pigs 
will continue to increase in importance as a biomedical model for both discovery and for 
clinical trials.  However, due to timeline differences between mice and pigs associated 
with development and generation interval, genetic engineering in swine requires special 
consideration for the impact of genetic engineering strategies on future logistics and costs.  
This consideration is particularly important in regard to maintenance and propagation of 
animals with multiple genetic modifications. 
For example, suppose that a project required four genetic modifications, and for 
breeding purposes, suppose that these modifications needed to be in a homozygous state. 
Further, suppose that for each transgene a particular range of transgene expression is 
acceptable. This scenario is likely to be required for xenotransplantation (Zhou et al., 
2005) or for engineered biosynthetic pathways (Rees et al., 1990). One strategy could 
involve cointegration of all four transgenes through random concatenation and integration 
via pronuclear microinjection or transfection of cultured cells followed by somatic cell 
nuclear transfer (SCNT). However, this strategy relies on the assumption that a sufficient 
number of founder animals could be produced to identify an individual animal that has 
acceptable levels of expression of each of the four transgenes. Although this strategy is 
technically possible, it does not appear likely that success would be guaranteed within the 
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scope of most budgets. For those projects in which all four of the transgenes require 
expression in the same cell type, it may be possible to develop screening methods for 
expression in cultured cells prior to SCNT to enrich for founders that provide appropriate 
expression of the transgenes. However, when expression of the transgenes is required in 
separate cell types or when the target cell type cannot be cultured, this strategy is not 
feasible. Yet when this strategy is successful, all of the transgenes are genetically linked 
and will be inherited as a single linkage group: an animal that inherits one transgene 
inherits all transgenes. 
A second strategy may be to produce founder animals in a stepwise progression, 
such that each transgene is added individually and a founder with acceptable expression 
is selected as the genetics for the next step. In the end, it is likely that a combination of 
transgene integrations could be obtained that provided an appropriate expression pattern 
and level for each transgene. However, upon propagation of this genotype, each 
transgene would segregate independently. In an outcross between a wild-type animal and 
a founder that is hemizygous for four transgenes, only 1/16 of the progeny would inherit 
all four transgenes based on Mendelian inheritance and independent assortment. 
Although this proportion of the progeny may be acceptable in mice for some projects, it 
will rarely be practical in swine. However, the scenario at hand supposes that each 
transgene needs to be rendered homozygous. Upon breeding of two animals that carry all 
four transgenes in a hemizygous state, only 1/256 of the progeny are expected to harbor 
all four transgenes in a homozygous state. It does not seem likely that independent 
integration would be a feasible approach for most goals. Similar issues arise if a viral-, 
retroviral-, or transposon-based strategy is selected. 
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A third approach, and the interest of this chapter, would be a stepwise strategy 
that placed each new transgene adjacent to the previous transgene(s) such that each 
modification becomes genetically linked to all previous modifications. At each step, the 
additional transgene could be evaluated for expression and impact on previously inserted 
transgenes. Each new transgene could be modified for increased or decreased expression 
as well as genetically insulated when transgenes were found to interact in an unwanted 
way.  In the end, transmission of the desired genotype in a wild-type cross would be to 
one-half of the progeny. Upon breeding of two hemizygous animals, one-quarter of the 
progeny would be expected to be homozygous. These efficiencies are comparable to 
single gene modifications and are therefore well within the realm of feasibility. 
Currently, there are two methods that can enable this third strategy of stacking 
each transgene within a previously selected locus. The first strategy would be through the 
use of homologous recombination. The second strategy would be through the use of a 
site-specific recombinase. This chapter describes a methodology for the use of bacterial 
recombinases for transgene stacking. In addition, the project described here combines 
gene stacking with gene targeting such that a series of transgenes will be placed within a 
disrupted locus, alpha-1,3-galactosyltransferase (GGTA1) (Figure 1). 
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Figure 1. Strategy to sequentially stack transgenes in a site-specific manner 
through the use of a dual recombinase-mediated gene-stacking system.  
(A) A PhiC31 attB site is inserted into the host genome, represented by site-specific 
integration by homologous recombination. The marker gene is flanked by loxP sites and 
will be excised at a later time by the use of Cre recombinase. (B) The PhiC31 integrase 
mediates recombination between the attB docking site (integrated into the genome) and 
the attP donor site (plasmid). The donor vector contains the gene of interest to be inserted, 
a PhiC31 attP site, a selectable marker, a loxP site, and two heterologous docking sites 
(R4 attB and Bxb1 attB).  The PhiC31 attP site will recombine with the PhiC31 attB 
docking site that was previously inserted into the genome. The marker gene will allow for 
selection to isolate cells that have undergone the PhiC31 recombination event. The loxP 
site will allow the removal of unwanted DNA (vector backbone and the marker). The R4 
attB and Bxb1 attB sites are introduced for the future addition of genes. (C) The 
unwanted DNA that has been introduced in (A) and (B) above can be removed using the 
Cre-loxP system. In the presence of Cre recombinase, sequence between loxP sites is 
excised. In this case, the two outermost loxP sites facilitate removal of the unwanted 
DNA (the two selectable markers, a PhiC31 attL site, and vector plasmid components). It 
should be noted that there are three possibilities for the Cre excision. In addition to the 
excision described previously (the first and third loxP sites), excision can also occur 
between the first and second loxP sites, and between the second and third loxP sites. 
Although recombination with the internal loxP will not be the predominant recombination, 
screening strategies must be designed to confirm removal of all unwanted DNA. (D) 
Additional genes of interest can be added through the use of alternating recombinase. An 
R4-mediated event is depicted. The components and mechanism are the same as in (B), 
with the exception that the recombination att sites originate from phage R4 and the 
PhiC31 attB site is reintroduced for future use. Since the various phage systems do not 
cross-react, the different integrases can be used in any order in subsequent steps. 
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Gene-Stacking Strategy 
 
There are several recombination systems that work efficiently for genetic 
engineering strategies, and each has individual strengths and weaknesses. The Flp-FRT 
and Cre-loxP recombinase systems are reversible and thus facilitate both site-specific 
integration and excision (Nagy, 2000; Wang et al., 2011). However, these systems favor 
excision rather than insertion (Nagy, 2000; Wang et al., 2011). While some 
recombination systems have reversible reactions, several do not. When integration alone 
is the goal, recombinases that perform only the integration reaction would be 
advantageous. In this instance, once a transgene is integrated, the transgene cannot be 
excised by the recombinase alone. There are several phage integrases that have this 
property: PhiC31 (Groth et al., 2000), Bxb1 (Mediavilla et al., 2000; Kim et al., 2003) 
and R4 (Matsuura et al., 1996; Olivares et al., 2001).  
Recombination by these phage integrases is carried out between two recognition 
sites, the bacterial attachment (attB) and phage attachment (attP) sites (Figure 2). After 
the reaction, the recombined attachment sites create two unique sequences/sites, 
attachment Left (attL) and attachment Right (attR) sites. The newly created attL and attR 
sites are unrecognizable by the phage integrase, thus creating an irreversible integration 
reaction (Thorpe & Smith, 1998; Thorpe et al., 2000). The phage integrases therefore 
provide an opportunity for site-specific integration without the possibility of excision by 
the same enzyme.  
This chapter describes a gene-stacking system that uses an integrating 
recombinase system (PhiC31/att) for transgene insertion, and in conjunction, an excision 
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favoring recombinase system (Cre-loxP) to remove DNA that becomes superfluous after 
integration. Although the overall strategy is likely feasible in any eukaryotic cell, this 
protocol references porcine fibroblasts. Methods are described to: (i) generate cells that 
contain a prepositioned PhiC31 attB site (PhiC31 docking site); (ii) transfect a PhiC31 
expression vector and a PhiC31 attP donor plasmid (PhiC31 donor site, with transgene); 
(iii) remove undesirable DNA (E. coli vector backbone and selectable marker) by the 
Cre-loxP system; and (iv) a strategy to stack multiple genes using a dual recombinase 
system (PhiC31 and R4 or Bxb1). See Figure 1 for a graphical outline of the methods 
listed. Table 1 provides an experimental outline. 
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Figure 2. Site-specific integration of PhiC31 attP into preintegrated 
chromosomal attB. (A) The heterotypic attB (35 bp) and attP (39 bp) sequences for 
PhiC31 attachment sites.  (B) Graphical representation of PhiC31 integrase mediating the 
integration of a transgene donor plasmid that contains an attP site into a previously 
chromosomally integrated attB site within a targeted location. Once integrated, the donor 
plasmid is flanked by attL and attR sequences. 
 
 
 
 
 
 
 
 
A)  attB:  5’ - GGTGCCAGGGCGTGCCC TTG GGCTCCCCGGGCGCG- 3’ 
 
 attP: 5’ - ccccaactggggtaacct TTG agttctctcagttggggg- 3’ 
 
 attL: 5’ - GGTGCCAGGGCGTGCCC TTG agttctctcagttggggg - 3’ 
 
 attR: 5’ - ccccaactggggtaacct TTG GGCTCCCCGGGCGCG - 3’ 
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Table 1. The Basic Steps Needed to Perform Irreversible Gene Stacking 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step Action 
1 Develop a strategy for stable integration of a PhiC31 attB-docking 
site. 
2 Generation of cell lines that contain docking site. 
3 Develop and execute a strategy to ligate gene of interest into the 
pBB53 vector (donor PhiC31 attP vector).  
4 Transfect a PhiC31 expression vector, a donor attP vector, and a 
docking attB vector to determine intramolecular integration 
between the attP and attB vectors. 
5 Transfection and generation of individual stable integration events 
mediated by PhiC31 recombination. 
6 Analysis of stable integrations. 
7 Removal of unneeded DNA (E. coli vector backbone and 
selectable marker). !
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Materials and Methods 
 
PhiC31 Vector Maps and Details 
Three components are required to achieve gene stacking mediated by a site-
specific integration. These components include the bacterial attachment site (attB), the 
phage attachment site (attP), and an integrase that mediates recombination between the 
two short att sites (Kuhstoss and Rao, 1991; Rausch and Lehmann, 1991; Thorpe et al., 
2000). This system is best described for the integrase of Streptomyces phage PhiC31, 
which normally mediates the integration of the phage genome into the bacterial 
chromosome through the host attB and phage attP recombination sites. The minimal 
functional size has been determined to be 34 and 39 bp for the attB and attP sites, 
respectively (Groth et al., 2000). The two sequences share only a common three-bp 
central region (TTG), which is flanked by imperfect repeats. Recombination between the 
two attachment sites creates two hybrid sites, which are referenced as attL and attR 
(Thorpe et al., 2000; Smith et al., 2004). The attL and attR sequences are not substrates 
for the PhiC31 recombinase, thus making this a unidirectional tool. In our gene-stacking 
approach, we have chosen to follow in suit with the natural context of the attB located in 
the host genome, where it serves as a docking site (see Figures 1 and 2). The attP site is 
located in the incoming donor vector, to mimic the phage att P integration into the 
bacterial host attB. This selection is arbitrary, since the integration can be accomplished 
in either direction (Groth et al., 2000; Thyagarajan et al., 2001).  Several mammalian 
expression vectors have been generated and proven functional in mammalian cells. We 
	   30 
have been able to confirm the utility of two different vectors (Groth et al., 2000; 
Raymond & Soriano, 2007) in pig cells. The data presented in this chapter were 
generated with the integrase-expression vector, pCMVint (Groth et al., 2000). 
 
a. PhiC31 gene-stacking vectors 
i. The PhiC31 expression vector, pCMVint, was previously described (Groth et al., 
2000). 
ii. To generate the PhiC31 attB docking site, we chose to use a gene-targeting 
strategy via homologous recombination. We generated a vector to target the 
porcine GGTA1gene. The method to generate a GGTA1 gene-targeting vector 
has previously been described (Beaton et al., 2013). We have since made a 
modification to the targeting vector used in that experiment. The minimum 
PhiC31 attB docking site (Groth et al., 2000) was inserted into pBB7 to make 
pBB18 (Figure 3A) and used to create a heterozygous GGTA1 targeted allele 
that harbors a PhiC31 attB. A similar strategy can be applied to any genomic 
target of interest. 
iii. To generate a universal PhiC31 attP donor plasmid, we modified an attP-
containing plasmid, pDRAV-3 (Osterwalder et al., 2010). The generated 
plasmid (pBB53) was created with a strategically located multiple cloning 
region that is ready to receive a user’s gene of interest (Figure 3B). The donor 
plasmid contains a selectable marker (Hygromycin B; Invitrogen) to select for 
integration. 
b. Cloning and preparation of plasmids 
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i. Clone the gene of interest (must be a self-contained functional unit) into the 
multiple cloning region of pBB53 using the appropriate restriction enzymes and 
buffers. 
1. Ligation of transgene into pBB53. (See Notes 1 and 2) 
a. Set up 20 µL ligation reaction.  
Ingredient Volume 
PhiC31 empty donor vector (pBB53) 1.0 µL (150-200 ng)  
DNA insert 1.0 µL (250-300 ng) 
10 X T4 DNA Ligase buffer 2.0 µL 
T4 DNA Ligase 1.0 µL  
H2O 16 µL 
Total reaction 20.0 µL 
 
b. Incubate reaction at 24 – 26°C for 1 h (sticky-end ligation) or 
overnight at 16°C (for blunt-end ligations). 
2. Transform ligation product into E. coli. 
We recommend transforming high-efficiency competent cells with 2 µL of 
the 20 µL reaction following the protocol provided with the competent 
cells. Plate the transformed bacteria on 50 – 100 µg/mL ampicillin LB 
agar plates and allow single colony clones to form overnight at 37°C. 
3. Isolate and identify clones with the correct insert. 
a. Depending on the total colony counts (generally expect 50 – 500 
colonies), randomly pick 5 – 30 colonies and grow each clone in 3 
mL of LB broth with 50 – 100 µg/mL ampicillin at 37°C overnight, 
with shaking. 
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b. The following day, purify the construct using a plasmid 
purification kit or alkaline lysis protocol. Verify insert using either 
polymerase chain reaction (PCR) or restriction enzyme diagnostics. 
c. Grow a positive clone containing the insert in an appropriate 
amount of LB ampicillin broth (500 mL culture to produce a large 
quantity of plasmid DNA), and purify the construct using a 
plasmid purification kit or alkaline lysis protocol. Verify clone 
with either PCR or restriction enzyme diagnostics. 
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Figure 3. Graphical representation of PhiC31 attB and attP vectors.  
(A) This plasmid was used to introduce the PhiC31 attB docking site into the pig genome 
at the GGTA1 locus. This targeting vector consisted of sequence homologous to the 
porcine GGTA1 gene, a mammalianized neomycin-resistant gene flanked by loxP sites, a 
PhiC31 attB docking site (red block), and a transgene. (B) The PhiC31 attP donor 
plasmid was created to contain a mammalianized Hygromycin B resistance gene, a loxP 
site, the PhiC31 donor attP site (orange block), an R4 attB site (light blue box), a Bxb1 
attB site (pink box), and a series of multiple cloning sites (MCS). The multiple cloning 
sites were designed to receive the gene of interest. 
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Intramolecular Integration Assay 
We have observed that the efficiency of PhiC31-mediated recombination differs 
between donor plasmids (and likely integration sites). This efficiency can be estimated 
prior to experimental procedures by transient transfection. To verify that the precise 
recombination between the PhiC31 attB docking site and the PhiC31 attP donor vector 
has occurred, the following intramolecular integration assay can be performed on crude 
cell lysate from cells that have been transiently transfected. The cells must be transfected 
with three pieces of DNA: (i) a PhiC31 expression vector that will transiently express the 
PhiC31 integrase (i.e., pCMVint); (ii) the PhiC31 attB docking site vector (i.e., pBB18, 
the GGTA1 targeting vector that contains the PhiC31 attB); and (iii) the PhiC31 attP 
donor site plasmid (plasmid pBB53 with inserted gene of interest). The goal of this assay 
is to determine if the reaction between the two att sites is being catalyzed by the 
recombinase in the cell type and cell culture conditions that are being used. A PCR assay 
is performed using primers that flank the newly created attL or attR site. 
The proper conditions and ratios have been optimized for porcine fibroblasts 
(see Note 3 and Figure 4). The described protocol is per manufacturer recommendations, 
FuGENE HD (Promega; Madison, WI). We recommend using a 1:10 ratio of integrase 
plasmid to donor vector. 
 
a.  Culture porcine fibroblast cells in complete medium (Dulbecco’s modified Eagle’s 
medium (DMEM) (Cellgro) containing 2.77 mM glucose, 1.99 mM L-glutamine, and 
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0.5 mM sodium pyruvate, supplemented with 1 mM L-alanyl-L-glutamine (Cellgro) 
and 12% fetal bovine serum (FBS)). Porcine fibroblasts should be cultured at 38.5°C, 
with 5.5% CO2, 5.0% O2, and 100% humidity. 
b.  Passage cells and plate them at a density of 30,000 cells/well in a 24-well plate. The 
cells will be ready to be transfected the next day or when they are at 50 – 60% 
confluency. 
c.  Transfect the cells according to manufacturer instructions using a lipid-based 
transfection method (see Note 5). The protocol uses a reagent to DNA ratio of 3.5:1. 
When transfecting a single well of a 24-well plate, ~ 600 ng DNA are to be transfected. 
1.      Allow FuGENE HD Transfection Reagent to reach room temperature. 
2.      Mix by inverting or vortexing briefly. No precipitate should be visible. 
3.  Dilute a total of ~ 600 ng plasmid DNA to a volume of 25 µL in water in a 1.5-
mL tube (see below). 
Transfection is to be performed with the three DNA components at a 
1:10:10 ratio (PhiC31 integrase:attP-containing plasmid:attB containing 
plasmid). Transfections are to be performed using supercoiled plasmid 
DNA for all three vectors. Transfect 30 ng PhiC31 vector, 300 ng attB 
vector, and 300 ng attP vector. 
4.  Add 2 µL FuGENE HD to same tube. Mix by pipetting the entire 27 µL, eight 
times. 
5.      Incubate for 5 – 10 min at room temperature. 
6.  Add 500 µL fresh complete medium to the 27 µL of the DNA:lipid complex. 
Mix gently by pipetting. 
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7.  Aspirate the medium from a well with cells and replace with transfection 
solution that was prepared in Step 6. 
8.      Return to gas controlled incubator at 38.5°C for 4 h. 
9.      Transfer plate to a gas controlled incubator at 30°C for ~ 44 h. 
10.  Harvest cells by trypsinization, resuspend in 40 µL lysis buffer (40 mM Tris, 
pH 8.9; 0.9% Triton X-100; 0.9% Nonidet P-40; 0.4 mg/mL proteinase K) and 
incubate at 65°C for 15 min to lyse the cells followed by 95°C for 10 min to 
inactivate the proteinase K. 
11.  Perform PCR to assay for intramolecular integration between the attP and attB 
vectors. A PCR assay should be designed using primers that detect the junction 
flanking the newly created attL or attR site. 
12.    Evaluate the PCR by electrophoresis on an agarose gel. 
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Figure 4. Determination of the culture temperature and the DNA ratios of 
PhiC31 integrase to attP donor vector.  
To calculate the occurrence of the recombination event, a PCR that flanks the junction of 
a PhiC31 attR was utilized. The yield of PCR product estimates recombination events 
that occurred in a pool of cells. Analysis was performed using ImageJ software 
(http://rsbweb.nih.gov/ij/) by calculating the density of the bands (arbitrary units). The 
data represent mean band density ±SD (n = 4 transfections). PhiC31 dependent 
integration is more efficient at 30°C as compared to 38.5°C. 
	   38 
Culture and Transfection of Porcine Fibroblast Cells 
  To demonstrate the efficacy of this protocol, cells were generated that contain the 
PhiC31 attB site within the GGTA1 locus as per Beaton et al. (2013). These cells serve as 
a recipient for the second piece of DNA, the donor vector that contains a PhiC31 attP site 
and a transgene. The third and final DNA is a mammalian expression vector that contains 
the coding sequence for the PhiC31 recombinase (pCMVint). The strategy for integration 
of the donor attP vector into the established GGTA1-located attB docking site is to co-
transfect the two vectors, pCMVint (PhiC31 expression vector) and pBB53, which 
includes the gene of interest (PhiC31 attP donor vector). 
The transfection method is similar to the previous method outlined in the 
intramolecular integration assay. The major differences are that after the transfection, the 
transfected cells are split onto 100-mm tissue culture plates and put under Hygromycin B 
selection. 
 
a. Culture porcine fibroblast cells in complete medium, (DMEM containing 2.77 mM 
glucose, 1.99 mM L-glutamine, and 0.5 mM sodium pyruvate, supplemented with 1 mM 
L-alanyl-L-glutamine and 12% FBS). Porcine fibroblasts should be cultured at 38.5°C 
with 5.5% CO2, 5.0% O2, and 100% humidity. 
b. Passage cells and plate them at a density of 30,000 cells/well in a 24-well plate. The 
cells will be ready to be transfected the next day when they are 50-60% confluent (see 
Note 4). 
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c. Transfect the cells according to manufacturer instructions using a lipid-based 
transfection method (see Note 5). The protocol uses a reagent to DNA ratio of 3.5:1. 
When transfecting a single well of a 24-well plate, a total of ~ 600 ng DNA is used. 
1.   Allow FuGENE HD Transfection Reagent to reach room temperature. 
2.   Mix by inverting or vortexing briefly. No precipitate should be visible. 
3.   Dilute a total of ~ 600 ng plasmid DNA to a volume of 25 µL in water in a 1.5-mL 
tube (see below). 
Transfection is to be performed with the PhiC31 expression vector and the attP 
donor vector at a 1:10 ratio (PhiC31 integrase:attP-containing plasmid). 
Transfections are to be performed using supercoiled plasmid DNA for both vectors. 
Transfect 55 ng pCMVint and 550 ng attB donor vector. 
4.   Add 2 µL FuGENE HD to same tube. Mix entire 27 µL by pipetting, eight times. 
5.   Incubate for 5 – 10 min at room temperature. 
6.   Add 500 µL fresh, complete medium to the 27 µL of the DNA:lipid complex. Mix 
gently by pipetting. 
7.   Aspirate the medium from a well with cells and replace with transfection solution that 
was prepared in Step 6. 
8.   Incubate the cells at 38.5°C under normal porcine cell culture conditions for 4 h. 
9.   Transfer plate to 30°C for ~ 44 h. 
10. Forty-eight hours post transfection, split cells onto ten 100-mm culture plates with 6 
mL complete medium. 
11. Twenty-four hours post Step 10, administer Hygromycin B drug selection. Add 1 mL 
of complete medium that has Hygromycin B (1750 mg/L), which is a 7× 
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concentration. The 7× concentration allows the entire drug selection medium on the 
plates to be equivalent to 1× concentration. 
12. Culture the cells for 13 days. A medium change can be performed after 7 – 9 days of 
culture using 1× concentration Hygromycin B (250 mg/L) in complete medium. 
13. After a total of 13 days in Hygromycin medium, colonies should range in size from 5 
to 15 mm. 
14. Harvest the cells by trypsinization. We recommend using cloning cylinders as a 
method to harvest individual colonies. Two-thirds of cells harvested are transferred to 
one well of a 24-well tissue culture plate for expansion, and one-third of cells isolated 
are used for PCR analysis of integration (user-developed assay from the transient 
assays above). 
a. Pellet assay cells by centrifugation. 
b. Remove supernatant and resuspend cell pellet in 5 µL lysis buffer (40 mM Tris, pH 
8.9; 0.9% Triton X-100; 0.9% Nonidet P-40; 0.4 mg/mL proteinase K) and 
incubate at 65°C for 15 min to lyse the cells followed by 95°C for 10 min to 
inactivate the proteinase K. 
15. Perform PCR to assay for intramolecular integration between the attP and attB 
vectors. A PCR assay is performed using primers that flank the newly created attL or 
attR site. 
16. Evaluate the PCR by electrophoresis on an agarose gel. 
17. Expand and cryopreserve positive colonies. SCNT can then be performed to generate 
fetuses for fibroblast collection for additional genetic manipulations or live pigs with 
the PhiC31 stacked transgene. 
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Cre-loxP-Mediated Excision of Unwanted DNA by Transient Expression of Cre 
Recombinase 
  To ensure expression of the transgene, it is important to remove plasmid 
sequences (Shani, 1986). In addition, the presence of a selectable marker can also 
influence the expression of neighboring genes (Fiering et al., 1995). Further, removal of 
superfluous DNA presents the possibility of recycling the selectable marker, as 
demonstrated in mouse embryonic stem cells (Rossant & Nagy, 1995; Abuin & Bradley, 
1996; Nagy & Rossant, 1996). In this method, removal of all unwanted sequences is 
facilitated by Cre recombinase (Nagy et al., 1998). Cre expression is provided by 
transient expression in cultured cells. The transfection method that has been optimized is 
a modification of the electroporation methods described by Ross et al. (2010) and Beaton 
et al. (2013). We have been able to achieve an efficiency of 82.1% through the transient 
expression of a mammalianized Cre-expression vector (Table 2). 
 
1.   Culture porcine fibroblast cells in complete medium, (DMEM containing 2.77 mM 
glucose, 1.99 mM L-glutamine, and 0.5 mM sodium pyruvate, supplemented with 1 
mM L-alanyl-L-glutamine and 12% FBS). Porcine fibroblasts should be cultured at 
38.5°C, with 5.5% CO2, 5.0% O2, and 100% humidity. 
2.   Harvest fibroblasts by trypsinization and resuspend the cells at a concentration of 
1×106 cells/mL in an electroporation medium (25% OptiMEM (Invitrogen) + 75% 
buffered KCl (135 mM KCl; 15 mM Tris; 11.3 mM N, N-Bis(2-hydroxyethyl)-2-
aminoethanesulfonic acid (BES); 3.7 mM 1,4-Piperazinediethanesulfonic acid 
(PIPES), pH 7.3). 
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3.  In a 4-mm cuvette, aliquot 400 µL of the cell suspension (400,000 cells) and add 7.5 
µg of supercoiled pCAG-Cre:GFP (Addgene plasmid 13776), a mammalian Cre-
expression vector (Matsuda & Cepko, 2007). 
4.  Using a square wave generator, electroporate the cells at 490 volts for three pulses at 
1 ms per pulse. 
5.  After the electroporation, resuspend the cells in a total volume of 10 mL complete 
medium. 
6.  Aliquot 5 µL of the 10 mL suspension to 7 mL of complete medium in a 100-mm 
tissue culture plate. This dilution is required in order to have a clonal density of 1 – 
10 colonies per culture plate. Perform this dilution onto 5 – 20 plates. Generally, 
fewer than five plates are required. 
7.  After 7 days, change medium with fresh complete medium (as in Step 1). 
8.  Allow cells to grow for an additional 6 days without any selection. After a total of 
13 days in culture after the transfection, colonies should range in size from 5 to 15 
mm. 
9.  Harvest the cells by trypsinization. We recommend using cloning cylinders as a 
method to harvest individual colonies. Two-thirds of cells harvested are transferred to 
one well of a 24-well tissue culture plate for expansion, and one-third of cells isolated 
are used for PCR analysis of Cre-loxP-mediated excision of unwanted DNA. 
a.  Pellet assay cells by centrifugation. 
b.  Remove supernatant and resuspend cell pellet in 5 µL lysis buffer (40 mM Tris, pH 
8.9; 0.9% Triton X-100; 0.9% Nonidet P-40; 0.4 mg/mL proteinase K) and 
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incubate at 65°C for 15 min to lyse the cells, followed by 95°C for 10 min to 
inactivate the proteinase K. 
10. Screen the colonies by PCR to determine which colonies have undergone the Cre-
mediated excision. A PCR screen needs to be designed to flank the unwanted DNA in 
order to confirm the excision. 
11. Expand and cryopreserve positive colonies. SCNT can then be performed to generate 
fetuses for fibroblast collection for additional genetic manipulations or live pigs with 
the Cre-excised genotype. 
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Table 2. Results of Cre-loxP-Mediated Deletion of a Selectable Marker 
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Summary 
We would like to note that the given protocol demonstrates the addition of a 
targeted PhiC31 attachment site (attB), followed by the PhiC31-mediated integration of a 
PhiC31 attachment site (attP) donor vector. We have also given an approach to remove 
unwanted DNA by the Cre-loxP system using transient expression of Cre for excision. 
The final contribution is a gene-stacking strategy that has unlimited potential if a dual 
recombinase attachment system is employed, as described in Figure 1. The gene-stacking 
system presented is a straightforward method that is unidirectional, site-specific, and 
enables the sequential insertion of multiple transgenes. 
 
Notes 
1. If assistance with DNA ligations, E. coli transformations, restriction enzyme analysis, 
or DNA sequencing is needed, we recommend you consult product manuals or 
protocol literature such as Molecular Cloning: A Laboratory Manual (Sambrook et al., 
1989) or Current Protocols in Molecular Biology (Ausubel et al., 2002). 
2. For all restriction enzymes and ligation reactions required, we recommend following 
manufacturer directions; use the protocol given in this chapter as guidance only. 
3. The transfection method has been optimized for the ratio of DNA concentration 
(PhiC31 expression vector:attP donor vector). In addition, we performed a temperature 
optimization that would allow for the most suitable reaction to occur. We chose to 
explore varying ratios due to the wide range in ratios that have previously been 
reported using PhiC31 in mammalian culture (Groth et al., 2000; Thyagarajan et al., 
2001; Chalberg et al., 2006). Groman and Suzuki (1962) reported that phages’ 
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reproduction efficiency varies depending on temperature. In the reported data, phage 
reproduction is drastically reduced at temperatures above 37°C. Porcine cell culture is 
performed at 38.5°C. Therefore, PhiC31 expression may not be optimal under normal 
porcine cell culture conditions. The results from varying ratios and the temperature 
comparison of 30°C and 38.5°C are shown in Figure 4. 
4. If transfection of larger plates is desired, the amount of each DNA and the transfection 
reagent should be scaled. We used the amounts of each DNA to ensure a low level of 
background, which allowed us to efficiently pick well-isolated colonies. 
5. For the transfections performed in the experiments demonstrated, we determined that 
when using FuGENE HD (Promega), ~ 90% of porcine cells are transfected using 
reporter DNA (data not shown). Therefore, all experiments performed using PhiC31 
have been performed using the transfection reagent FuGENE HD. 
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CHAPTER III 
 
 
THE EFFECT OF DONOR DNA HOMOLOGY LENGTH ON THE OUTCOME 
OF NUCLEASE-MEDIATED GENE TARGETING 
 
 
Abstract 
 
Gene editing techniques are increasing in their availability and ease of use.  These 
techniques are an attractive alternative to conventional gene targeting methods via 
homologous recombination due to the ease of use and the efficiency of programmable 
nucleases.  We have previously produced cytidine monophosphate-N-acetylneuraminic 
acid hydroxylase (CMAH) knockout (KO) pigs in a Minnesota Miniature Pig genetic 
background.  These pigs were generated by using Zinc-Finger Nucleases (ZFNs) in 
combination with donor DNA containing a total length of homology of 1,600 bp (800 bp 
homology on each arm).  An additional targeted disruption of GGTA1 was desired in the 
CMAH -/- genetic background.  We used this opportunity to evaluate the effect of donor 
DNA homology length on nuclease-mediated gene targeting.  Initially we utilized ZFNs 
as a proof of concept to identify a correlation between the length of donor DNA 
homology and targeting efficiency by using the CMAH gene and then transitioned to 
Transcription Activator-Like Effector Nucleases (TALENs) to generate bi-allelic 
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modified GGTA1 cells.  Donor DNA was designed to symmetrically flank the predicted 
cleavage sites in CMAH and GGTA1 for both ZFN and TALEN cleavage sites, 
respectively.  For both genes, the length of total homology ranged from 60 – 1799 bp.  
Donor DNA alone did not result in detectable bi-allelic conversion of GGTA1.  As the 
length of donor DNA increased, the bi-allelic disruption of GGTA1 increased from 0.5% 
(TALENs alone, no donor DNA present) to a maximum of 3% (1,799 bp).  Inclusion of 
homologous donor DNA in TALEN transfections facilitated a higher incidence of bi-
allelically modified cells since bi-allelic disruption was increased in the presence of 
donor DNA, exogenous templates can affect non-homologous end joining (NHEJ). 
 
 
Introduction 
 
Genetic engineering technologies have advanced to a point where imagination and 
resources are the only limitations.  Genetic engineering of cell lines or animal models has 
traditionally utilized random integration or low-efficiency gene targeting through 
homologous recombination (HR).  As genetic engineering schemes become more 
elaborate, a need to generate precise modifications is required.  Specifically, more precise 
modifications will be of more interest rather than non-specific mutations.  In order to 
achieve targeted modifications, donor DNA that contains the desired sequence needs to 
be introduced.  HR is a normal cellular mechanism that occurs to repair damaged 
sequence through a double crossover event with the sister chromatid.  The efficiency of 
gene targeting through HR is relatively inefficient, ranging from 0.5% - 5.0% (Mansour 
et al., 1988; Hasty & Bradley, 1993; Rouet et al., 1994; Smih et al., 1995; Jasin, 1996).  It 
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should be noted that in order for HR to occur, genomic breakage of the target sequence is 
the rate-limiting factor (Song et al., 1985; Hasty & Bradley, 1993; 1994; Rouet et al., 
1994; Choulika et al., 1995).  
The introduction of programmable nucleases, specifically zinc-finger nucleases 
(ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly 
interspaced short palindromic repeats (CRISPR) associated protein 9 (Cas9) have enabled 
modification of target genomic sequences.  In principal, these tools induce double-strand 
breaks (DSB) at specific locations in the genome and result in either random mutations 
through non-homologous end joining (NHEJ) or stimulation of HR through homology 
directed repair (HDR) (Gaj et al., 2013).  In the pig, the different types of nucleases have 
been effective in generating targeted mutations through NHEJ [ZFNs (Hauschild et al., 
2011; Whyte et al., 2011; Yang et al., 2011), TALENs (Carlson et al., 2012; Tan et al., 
2013; Lee et al., 2014), CRISPR/Cas9 (Tan et al., 2013; Whitworth et al., 2014)], as well 
as through HR in the presence of donor DNA (Kwon et al., 2013; Tan et al., 2013; 
Whitworth et al., 2014). 
Pigs are considered a potential resource as organ donors for humans because of 
their compatible organ size and physiology (Ye et al., 1994; Dai et al., 2002; Lai et al., 
2002; Lai & Prather, 2003).  However, pig-to-human xenotransplantation has several 
immunological barriers to overcome.  Rapid rejection of grafted organs is primarily due 
to hyper acute rejection (HAR) (Sandrin & McKenzie, 1994; Joziasse & Oriol, 1999; 
Galili, 2001).  HAR is a response mediated by natural antibody reactivity followed by 
complement activation and cell lysis.  In an attempt to overcome a major xeno-antigen, 
N-glycolynlneuraminic acid (Neu5Gc), we have produced cytidine monophosphate-N-
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acetylneuraminic acid hydroxylase (CMAH) knockout (KO) pigs in a Minnesota 
Miniature Pig genetic background (Kwon et al., 2013).  Neu5Gc is a sialic acid, which is 
mediated by CMAH.  A mutation in the human CMAH gene results in the absence of 
Neu5Gc in humans.  The ablation of a second xeno-antigen gene (alpha 1,3 
galactosyltransferase, GGTA1) was desired in the CMAH -/- genetic background.  CMAH 
and GGTA1 are expressed on endothelial cells of most mammals, with the exception of 
humans (Galili et al., 1988; Muchmore et al., 1998; Varki, 2001; Basnet et al., 2010; 
Tahara et al., 2010).  Therefore, these epitopes are a potential target for human 
endogenous antibodies, and the ablation of these epitopes would not allow for human 
antibodies, directed to these epitopes, to reject the transplanted organs.   
 The objective of this project was to generate homozygous knockout cells and 
evaluate the role of donor DNAs with varying lengths of homology in TALEN-mediated 
gene targeting.  Here, we carried out a series of experiments by using nucleases (ZFNs & 
TALENs) to characterize the effect of donor DNA homology length during nuclease-
mediated gene targeting.  As a proof of principle, we used ZFNs as previously reported 
(Kwon et al., 2013) and determined that a minimum arm length of 35 bp will induce HR.  
In subsequent experiments to further evaluate the minimum length of homology, we used 
TALEN-mediated gene targeting.  Based upon our ZFN/CMAH observations, we 
expected to see gene targeting at the same frequency in our TALEN/GGTA1 experiments.  
Unexpectedly, we did not observe any gene targeting by HR with donor DNA, but 
instead demonstrated that the addition of donor DNA increases bi-allelic modifications 
when compared to TALEN-mediated editing in the absence of donor DNA.  
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Materials and Methods 
 
ZFN Design and Construction 
 Custom ZFN plasmids were designed and used as described in Kwon et al. (2013). 
 
Production of CMAH Small Donor DNAs 
To identify a minimum length of homology required to induce HR during ZFN-
mediated targeting, a series of donor DNA with varying lengths of homology were 
generated.  First two oligonucleotides containing short homology were annealed and then 
PCR was performed to extend the homology (Figure 5).  ZFN binding sites were 
modified and an in-frame stop codon was introduced to the donor DNA: 35 (A), 85 (B), 
and 125 (C) bp homology on each arm.  All oligonucleotides to generate the short donor 
DNAs are shown in Table 3. 
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Table 3. Primer sets used to generate small CMAH donor DNA with minimal 
homology length in ZFN-mediated gene targeting. 
 
Primers Sequences (5' - 3') 
CMAH-
smallF 
GGAATGGAAAGCCCAATTCATTAAAACAGAAAGGAAGTAGACACG
AGTCCACGGGCTGGTGAAGGACCTACAACCCAGAATTTACTGCCC 
CMAH-
smallR 
GGGCAGTAAATTCTGGGTTGTAGGTCCTTCACCAGCCCGTGGACTC
GTGTCTACTTCCTTTCTGTTTTAATGAATTGGGCTTTCCATTCC 
CMAH-
midF 
TTTCTGAACAGAGAAGACTAATCCAAACCCTGTCATTCCAGAGGAA
TGGAAAGCCC 
CMAH-
midR 
TACTTGTCTGCTGGGTGGGATTCCACGAAATACCCAGCAAAGGGGC
AGTAAATTCTGGGT 
CMAH-
longF 
GCAAGACTTCTAATCTACTAGAACTTTTGTTTTTCTGTGATTTCTGA
ACAGAG AAGACTA 
CMAH-
longR 
TATTAACTTATGCGTAAACACGTTATATAAAATATCCAGCCATACT
TGTCTGCTGGGTGG 
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Transfection of CMAH Donor DNAs and ZFNs 
Transfection conditions were a modification of Ross et al. (2010).  For gene 
targeting, 1 million wild-type porcine fibroblast cells were co-transfected with a pair of 
ZFN plasmids and donor DNA (600 ng total; 1:1:1 ratio).  By using a square wave 
generator (BTX Electro Cell Manipulator, Harvard Apparatus, Holliston, MA), the cells 
were electroporated at 490 V for 3 pulses at 1 millisecond per pulse.  ZFNs alone served 
as a control.  
 
DNA Isolation and Quantitative real-time PCR 
To identify the rate of gene targeting induced by HR, DNA was isolated from the 
transfected cells after three days.  Fifty ng of genomic DNA was used for PCR analysis. 
Quantitative real-time PCR was performed by using IQ SYBR Green Supermix (Bio-Rad 
Laboratories).  The PCR primers are shown in Table 4.  The PCR was performed on a 
MyiQ single color real-time thermal cycler (Bio-Rad).  The program used for 
amplification included an initial temperature of 94°C for 2 minutes followed by 40 cycles 
of 5 seconds at 94°C, 30 seconds at 60°C, and 30 seconds at 72°C. Real time 
fluorescence data was collected during the extension time.  Differences in gene targeting 
were compared by ANOVA and p<0.05 was considered significant.  Three biological 
replicates with two technical replicates were applied. 
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Table 4. Primer sets used for genotyping CMAH KO cells and pigs.  
 
Primers Sequences (5' - 3') 
CMAH-F AGGAAGTAGACACGAGTCCACG 
CMAH-R CATACTCTCTGTTTTCAGGCTGCTTG 
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TALEN Design and Construction 
A single TALEN pair was designed to target exon 4 of the porcine GGTA1 locus 
(NCBI: NM_213810) (Figure 6).  TALEN design and construction was completed by 
using ToolGen, Incorporated (toolgen.com). 
 
Targeting Vector Construction and Production of Small Donor DNAs 
A targeting construct was assembled from DNA isolated from female “Minnesota 
Miniature” porcine fetal fibroblasts (Cell Line: 104824; National Swine Resource and 
Research Center [NSRRC]).  A 2,389 bp GGTA1 genomic fragment, which includes most 
of exon 4, was generated by polymerase chain reaction (PCR) by using specific primers 
(Forward: 5'-TTCCACCCAGCATCCCTTCCCTCT-3' and Reverse: 5'-
TGGCCAAAATGGTCCTGCTGGCTC-3') and Q5 DNA polymerase (New England 
Biolabs, NEB, Ipswich, MA).  PCR amplification was repeated for 30 cycles of 10 
seconds at 98°C for denaturation, 30 seconds at 72°C for annealing, and 150 seconds at 
72°C for extension.  The PCR product was cloned into pCR-Blunt II-TOPO (Invitrogen, 
Grand Island, NY) to produce the plasmid pBB60.  Sanger sequencing (University of 
Missouri DNA Core Facility, Columbia, MO) and restriction enzyme diagnostics 
confirmed the sequence of the GGTA1 fragment.  Reverse PCR was performed to 
generate donor DNA that would contain a mutated TALEN cut site, stop codons in three 
reading frames, and unique restriction enzyme sites for future diagnostics.  The PCR was 
performed on pBB60 by using specific primers (Forward: 5'-
CTCGAGCCTGCAGGCAGGTAATTATGAAAC-3' and Reverse: 5'-
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CTACCCTATCTAGCATTGACAGAACCACTC-3') and the TaKaRa LA system 
(Takara Bio Inc., Japan).  PCR amplification was repeated for 30 cycles of 30 seconds at 
94°C for denaturation, 30 seconds at 54°C for annealing, 180 seconds at 68°C and 
increase by 6 seconds per cycle for extension, and with a final extension for 360 seconds 
at 72°C.  The PCR product was purified by ethanol precipitation; the 5' and 3' ends were 
phosphorylated (T4 PNK, NEB) and ligated together (T4 Ligase, NEB) prior to E. coli 
transformation (5α Competent, NEB).  Sanger sequencing (DNA Core Facility) 
confirmed the mutated sequence.  The targeting and mutated targeting constructs are 
graphically depicted and sequence differences are represented in Figure 6.   
Small donor DNAs with minimal homology sequence (total length of homology: 
60, 103, 211, 477, 895, and 1,799 bp) were amplified by PCR (EconoTaq DNA 
Polymerase, Lucigen, Madison, WI) by using primer sets shown in Table 5.  PCR 
amplification was repeated for 30 cycles of 15 seconds at 94°C for denaturation, 15 
seconds at 56°C for annealing, 30 seconds (short donor DNA: 86 bp, 129 bp, 237 bp, 495 
bp) or 120 seconds (long donor DNA: 921 bp, 1825 bp) at 72°C for extension, and with a 
final extension for 120 seconds at 72°C.  The PCR product was visualized on a 0.8% 
agarose gel, isolated, and purified from agarose by using β-Agarase I (NEB), followed by 
ethanol precipitation.   
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Table 5. Primer sets used for donor DNA with minimal homology length in the 
TALEN mediated gene targeting.  
 
Donor 
DNA 
Forward Primer 
(5' - 3') 
Reverse Primer 
(5' - 3') 
Donor 
DNA 
Size (bp) 
Left Arm 
Homology 
(bp) 
Right Arm 
Homology 
(bp) 
Total 
Homology 
(bp) 
TALEN 1 
ATGTCAAAGG
AAGAGTGGTT
CTGTCAATGC 
CATCATTTCA
TCATGTTTCA
TAATTACCTG
CCTGC 
86 30 30 60 
TALEN 2 
TTCCCAGGAG
AAAATAATGA
ATGTCAAAGG
AAGAGT 
AGATTAGAGG
AGACTTTCAT
CAACATCATT
TCA 
129 50 53 103 
TALEN 3 
ACCATATTCC
ACTCTGGGTG
T 
ACGGTGTCAG
TGAATCCTAC
TT 
237 102 109 211 
TALEN 4 
CCCAGACGGC
CCTGTCAGTT
CAT 
TGCCGGATCC
TTAAGCCAAA
GAGC 
503 254 223 477 
TALEN 5 
TGTGATGCGA
GGTGGGGCAT
CTGA 
AGGACAATG
GCAACATGGC
AGGAAGGA 
921 401 494 895 
TALEN 6 
TTCCACCCAG
CATCCCTTCC
CTC 
AGCTGGAATC
TCCAAGGCAT
CGTAGT 
1825 896 903 1799 
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Preparation of Porcine Fibroblast Cells and Culture Conditions 
Ear tissue was collected and minced from newborn piglets to create ear fibroblast 
cell lines from female CMAH KO Minnesota Miniature Pig genetic background (Kwon et 
al., 2013).  The minced tissue was digested in 20 mL of digestion medium (Dulbecco’s 
modified Eagle’s medium containing 2.77 mM glucose, 1.99 mM L-glutamine, 0.5 mM 
sodium pyruvate (Cellgro, Manassas, VA) supplemented with 200 units/mL collagenase 
and 25 Kunitz units/mL DNaseI) for 5 hours at 38.5°C.  After digestion, ear fibroblast 
cells were washed and cultured with DMEM, 15% fetal bovine serum (FBS, Cellgro) 
with 40 µg/mL gentamicin (Cellgro).  After overnight culture, cells were trypsinized and 
frozen at -80°C in aliquots of FBS with 10% dimethyl sulfide (DMSO, Sigma) and stored 
in liquid nitrogen. 
 
Transfection of Donor DNAs and TALENs Plasmids  
Transfection conditions were a modification of Ross et al. (2010) and as 
previously reported (Beaton & Wells, 2014).  Four replicates of eight transfections were 
conducted with porcine ear fibroblasts from a female CMAH KO Minnesota Miniature 
Pig (Kwon et al., 2013).  The fibroblast cells were cultured for 72 hours in complete 
medium (DMEM and 12% FBS) at 38.5°C in 5.5% CO2, 5% O2, and 89.5% N2 balanced 
humidified air.  Fibroblasts were harvested by using trypsin and re-suspended in 
complete medium at a density of 57,000 cells/mL.  Cells were plated at a density of 
28,500 cells (0.5 mL of suspension) per well in 8 wells (7 treatments and 1 control) of a 
24 well plate.  Approximately 24 hours post plating of the cells they reached 50 – 60% 
confluency and were ready to be transfected.  Left TALEN, Right TALEN, and the donor 
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DNA were co-transfected (600 ng total DNA; 1:1:1 ratio) by using FuGENE HD 
Transfection Reagent (Promega, Madison, WI).  Transfected cells were cultured in 
complete medium for 2 days, passaged and cultured for another 3 days. 
 
Screening and Analysis of Knock-out Cells and Pigs 
Five days after transfection, cells were analyzed by fluorescence-activated cell 
sorting (FACS).  Cells were trypsinized, washed with PBS, and centrifuged.  Cells were 
re-suspended in 1 mL PBS + 3% FBS and incubated with 10 µg Isolectin-B4-FITC 
(Sigma) for 1 hour at 4°C.  GGTA1 null cells were counter-selected by using flow 
cytometry as the α-1, 3-galactose (Gal) epitope is recognized by the specific lectin, IB4 
(MoFlo XDP, Beckman Coulter; University of Missouri Cell & Immunobiology Core 
Facility, Columbia, MO).  Three biological replicates were performed for each treatment.  
Flow sorted cells were pooled and cultured for 7 days.  After 7 days the cells were 
harvested and re-suspended in 30 µL of lysis buffer (40 mM Tris, pH 8.9; 0.9% Triton X-
100; 0.9% Nonidet P-40; 0.4 mg/mL proteinase K, (Sigma)), incubated at 65°C for 15 
minutes to disrupt the cells, and then heated to 95°C for 10 minutes to inactivate the 
proteinase K.  By using Q5 DNA polymerase (NEB), a single primer set was used for 
PCR analysis (Table 6).  The PCR was designed to amplify porcine GGTA1 sequence 
located outside of the recombination region homologous with the donor DNA template 
and resulted in an amplimer of 2,389 bp.  PCR amplification was repeated for 30 cycles 
of 10 seconds at 98°C for denaturation, 30 seconds at 72°C for annealing, and 150 
seconds at 72°C for extension.  
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One replicate of GGTA1 null cells were sorted and plated at clonal density to later 
perform analysis on single cell populations.  After 10 days, half of the cells were used for 
genotyping and half were expanded to be cryo-preserved for long-term preservation.  
Upon expansion of GGTA1 null cells, the lack of cell surface expression of GGTA1 was 
determined.  Fibroblast cells were washed with PBS, and stained with a 1:500 dilution of 
1 mG/mL Isolectin B4 (IB4)-FITC in PBS for 30 minutes at 4°C. 
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Table 6. Primer sets used for screening and genotyping GGTA1 KO cells and 
pigs.  
 
Primers Sequences (5' - 3') 
GGTA1-F TTCCACCCAGCATCCCTTCCCTCT 
GGTA1-R TGGCCAAAATGGTCCTGCTGGCTC 
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Somatic Cell Nuclear Transfer (SCNT) 
For SCNT, sow-derived oocytes were purchased from ART (Madison, WI). 
Cumulous oocyte complexes were aspirated from sow ovaries and then shipped overnight 
in maturation medium (TCM199 with 2.9 mM Hepes, 5 mg/mL insulin, 10 ng/mL EGF, 
0.5 mg/mL p-FSH, 0.91 mM pyruvate, 0.5 mM cysteine, 10% porcine follicular fluid, 25 
ng/mL gentamicin). Upon arrival, the oocytes were transferred into fresh medium and 
cultured for additional 20–24 hours. After 40– 42 h of maturation cumulus cells were 
removed from the oocytes by vortexing for 3 min in the presence of 0.1% hyaluronidase. 
The denuded oocytes were manipulated in the maturation medium supplemented with 7.0 
µg/mL cytochalasin B. The polar body along with a portion of the adjacent cytoplasm 
was removed, and a donor cell was placed in the perivitelline space as described 
previously (Lai & Prather, 2003).  A combination of two donor cell lines was used. The 
reconstructed embryos were then fused in a fusion medium (0.3 M mannitol, 0.1 mM 
CaCl2, 0.1 mM MgCl2, 0.5 mM Hepes) by using two DC pulses (1-sec interval) at 1.2 
kV/cm for 30 µsec (by using a BTX Electro Cell Manipulator, Harvard Apparatus, 
Holliston, MA). After fusion, fused embryos were fully activated with 200 mM 
thimerosal for 10 min in the dark followed by 8 mM dithiothreitol for 30 min (Machaty et 
al., 1997). Embryos were then incubated in PZM3 (Yoshioka et al., 2002) with 0.5 mM 
scriptaid, a histone deacetylase inhibitor, for 14–16 hours (Zhao et al., 2009; Zhao et al., 
2010). The following day the SCNT embryos were surgically transferred into the 
ampullary-isthmic junction of a surrogate at 0 or 1 day after observed estrus. 
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RNA Isolation and real-time RT-PCR 
Total RNA was extracted from WT-, CMAH KO-, and CMAH/GGTA1 double KO 
(DKO)-null pig fibroblast by using an RNeasy mini kit (Qiagen, Valencia, CA, USA). 
Real-time reverse transcriptase polymerase chain reaction (RT-PCR) was conducted by 
using an ABI ViiA™ 7 system (Applied Biosystems, Foster City, CA, USA) and SYBR 
Green as the double-stranded DNA-specific fluorescent dye (Bio-Rad, Hercules, CA, 
USA) (see Table 7 for RT-PCR primer sets). The pig ACTB gene was used as an internal 
control to normalize the RT-PCR efficiency and to quantify the expression of the genes in 
WT pig, homozygous CMAH KO, and homozygous CMAH/GGTA1 DKO pig derived 
mRNA. After normalization with ACTB mRNA, we compared the relative expression of 
each mRNA in the homozygous CMAH and homozygous CMAH/GGTA1 DKO pig-
derived genes with those of the controls. We performed RT-PCR on each sample 
independently and in triplicate. 
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Table 7. Primer sets used for detection of sialyltransferases mRNA expression.  
 
Antigen	   Gene	   Forward	  primer	  	  (5'	  -­‐	  3')	   Reverse	  primer	  	  (5'	  -­‐	  3')	   Product	  size	  (bp)	  
H-­‐D	  
antigen	  	  
ST3GAL1	   GCATCCTCTCCGTGATCTTC	   CAAGATGGTTGTCACGTTGG	   176	  
ST3	  GAL	  2	   AACCACCCACCATTTCATGT	   ACTTCACTGGGGCATAGGTG	   152	  
ST3	  GAL	  3	   GCTTCAAGTGGCAGGACTTC	   ATGAGGCCATTGTTGAAAGG	   193	  
ST3	  GAL	  4	   GCCATCACCAGCTATTCCAT	   GTGGGCAGATTCAGGGTAGA	   219	  
ST6	  GAL	  1	   TGTGTGACCAGGTGGATGTT	   TCCCAAGCAGGTAGATGTCC	   183	  
ST6	  GAL	  2	   ACCTGCCATGAAACCACACT	   GGTCTCCAGGAAGGAGAAGG	   151	  
Sialyl-­‐
Tn	  
antigen	  
ST6	  
GALNAC2	  
GGCTGGTTCACCATGATTCT	   AACACGGCCTTCTCAGTGAT	   209	  
ST6	  
GALNAC	  3	  
CTTCGAACTCACTATGGATAC	   GAGCCAGACTGGACTCTGTCCT	   467	  
ST6	  
GALNAC	  6	  
ATGAGTAGCAACAAAGAGCAG	   CCTGGGGCTTCTGCATCTTG	   478	  
Tn	  
antigen	  
GALNT1	   CTTTCACTCGCTGTGAACCA	   CTCTTCATTACGCCAGCACA	   227	  
GALNT2	   CAGCCTCCCAGTCTGACTTC	   AGCTGGGGGACTGTTTTCTT	   179	  
GALNT3	   TTGGCCTTTGTGTAAAACCAG	   TGCTTCAAGTCAAGTGGATTTC	   239	  
GALNT4	   ATTCCAGTGGCATTCTGTCC	   GACAGCTCGAGGTTCTCACC	   177	  
GALNT7	   TCAGGGTCTGAAAGGCAGTT	   TGTGGCAGTGCTTCAAAAAG	   152	  	   ACTB	   GAGGGCAGTAGCATCGCTTTAGTG	   GCACCTCAACCCGCTCCTAG	   179	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Figure 5. Designed ZFN and comparison of Donor DNA homology length.   
A) Schematic design of ZFN-mediated targeting of CMAH by using small donor DNAs.  
HR junction was amplified by PCR.  Green indicates homology region.  Blue indicates 
location of modified ZFN binding site with added in frame termination codon.  Three 
different donors were generated for the study: 35 (A), 85 (B), and 125 (C) bp homology 
on each arm. 
B) Efficiency of gene targeting through HR in ZFN-mediated targeting of CMAH.  Donor 
with the longest homology resulted in the highest efficiency of targeting (donor C). 
Targeting through HR was detected from donor A by using quantitative real-time PCR; 
however, we could not detect the PCR product on a gel. Different letters indicate 
statistical difference (p<0.05).    
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A) 
 
B) 
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C) 
 
Figure 6. Designed TALENs and comparison of homology length of Donor DNA.  
A) Designed TALENs to target porcine GGTA1.  The TALENs were designed to 
recognize 20 bp with a 12 bp spacer between the left and right TALENs.  The TALENs 
are designed to create a double stranded break in exon 4 of GGTA1.   
B) Targeted GGTA1 exon 4 sequence and mutated GGTA1 exon 4 donor DNA sequence.  
C) Graphical representation of donor DNA with 6 different lengths of homology. 
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Results 
 
Effects of the Homology Length of Donor DNA in ZFN-Mediated Gene Targeting 
The highest targeting efficiency was observed when the donor DNA with 125 bp 
homology on each arm was used and the efficiency was 10 times higher compared to the 
donor DNA with 35 bp homology (Figure 5).  No recombination event was detected in 
the negative control as was expected.  When the PCR products were examined by gel 
electrophoresis, we could not detect a visible PCR product from the 35 bp homology 
group.  However the highest intensity of PCR product was detected in the presence of 
donor DNA with the longest homology (donor C). 
 
Effects of the Homology Length of Donor DNA in TALEN-Mediated Bi-allelic 
Modifications 
To identify the minimal homology length of donor DNA that can induce HR at 
the targeting locus, a series of DNA fragments of various lengths homologous to GGTA1 
exon 4 were generated (Figure 6).  Each donor DNA was transiently transfected with 
TALENs into fibroblast cells that lack functional CMAH.  Fibroblast cells were recovered 
5 days after transfection and analyzed by FACS.  Bi-allelic modifications to the GGTA1 
gene were analyzed by counter-selection with IB4-FITC.  All treatments that included 
donor DNA resulted in higher amounts of GGTA1-null cells (Figure 7), with the largest 
quantity of GGTA1-null cells resulting from donor DNA with the longest length of 
homology.   To test if there was a statistical significance across the entire dataset, a 
pairwise Chi-squared analysis was performed and showed significance at p < .05.  To test 
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between treatment means, count data were analyzed using the Student’s T-Test.  Based 
upon our results, all treatments that contained TALEN expression vectors showed 
significance as compared to donor DNA alone.  Additionally, treatments that contained 
TALEN expression vector DNA and donor DNAs with the lengths associated with donor 
DNAs 2, 3, and 4 showed a significance of p <.05 as compared to TALEN expression 
vector alone.  However, there was not a significant difference between the treatments that 
contained both donor DNA and TALEN expression vectors. 
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Figure 7. Targeting of GGTA1 locus via TALENs and varying lengths of Donor 
DNA.    
A) Average IB4 negative cells are represented in each column along with the standard 
error of means (4 replicates).  GGTA1 null cells were counter-selected using flow 
cytometry post TALEN transfection, including controls wild-type Minnesota Miniature 
(WT IB4 +) cells, homozygous KO GGTA1 (D.KO IB4 -) cells (NSRRC), WT cells 
transfected with TALENs alone, and WT cells transfected with longest donor DNA 
(TALEN 6).                
B) All treatments compared to WT control, WT control transfected with TALENs alone, 
and longest donor DNA. 
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Disruption of GGTA1 Gene  
 When TALENs designed for the GGTA1 gene were introduced into female 
CMAH null fibroblast cells with donor DNA, GGTA1 null cells were detected.  After 
transfection and sorting of cells that lacked the Gal-epitope, the Gal negative cells were 
plated at clonal density.  DNA was isolated from 66 cell colonies, and then the DNA was 
used to determine the type of mutations within GGTA1 by PCR (data not shown).  Zero 
colonies showed targeted mutation of the GGTA1 gene via homologous recombination 
and six colonies showed targeted bi-allelic mutation of the GGTA1 gene via NHEJ with 
major deletions (395 – 716 bp).  A handful of colonies that did not have major deletions 
were also sequenced.  All contained a single bp deletion near the Right TALEN 
recognition site.  
 
Production of Bi-Allelic GGTA1 Knock-out Miniature Pigs in a CMAH-null Background 
 Upon screening for GGTA1 KO events by both flow cytometry and PCR, three 
cell colonies were used to produce CMAH/GGTA1 DKO pigs.  Two colonies (26 & 30) 
that harbored the same homozygous deletions of 395 bp and the colony (22) that harbored 
a homozygous deletion of 719 bp of GGTA1 were used to produce the CMAH/GGAT1 
DKO pigs.  A single SCNT was performed, 183 reconstructed embryos were transferred 
into a single surrogate, and produced 3 piglets (Figure 8).  Genotyping from the cloned 
pigs showed the expected deletions of the GGTA1 and CMAH genes (Figure 8). Two 
piglets harbored a 395 bp deletion, one piglet had a 716 bp deletion, and for all three 
piglets, the genotypes were bi-allelic modifications for the respective deletions (Figure 8).   
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 Since the IB4 lectin from Bandeiraea simplicifolia binds the Gal epitope (Hayes 
& Goldstein, 1974), a FITC conjugated IB4 lectin was applied to fibroblasts that were 
isolated from the tail of the live piglets.  In contrast to wild-type cells a fluorescence 
signal for IB4 could not be detected on cells from any of the three piglets (Figure 8) 
indicating the lack of Gal-epitope and implying a loss of function. 
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Figure 8. CMAH/GGTA1 DKO Pigs.  A) Image of CMAH/GGTA1 DKO pigs.  B) 
Genotyping of DKO Pigs, GGTA1 locus.  For genotyping, PCR was performed to verify 
KO of GGTA1 by amplifying the entire exon 4 junction (2,389 bp for the endogenous 
gene).  Lane 1: DNA Ladder, Lambda Genome digested with BstEII (NEB), Lane 2: 
empty lane, Lane 3: Piglet 71-1, Lane 4: Piglet 71-2, Lane 5: Piglet 71-3, Lane 6: Wild-
type (WT) control, and Lane 7: H2O negative control.  PCR products from piglets 71-1 
and 71-3 indicate that both alleles have a major deletion of 395 bp (lanes 3 and 5, 
respectively). PCR product from piglet 71-2 indicates that both alleles have a major 
deletion of 716 bp (lane 4).  C) Genotyping of DKO Pigs, CMAH locus.  For genotyping, 
a PCR was run to verify KO of CMAH.  A left arm PCR was performed to amplify the 
left HR junction (1.2 kb for endogenous WT, a 3.2 kb for KO by HR, and 1.7 kb for 
partial insertion of selectable marker) by using ScS5 and CMAH R (Kwon et al., 
2013).  PCR products from biallelic CMAH KO pigs confirmed one allele was targeted 
through HR and the other allele was targeted through NHEJ; lane 1: H2O negative 
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control, lane 2 - 4: piglets 71-1, 2, & 3, lane 5: WT control, lane 6: heterozygous targeted 
CMAH control pig, lane 7: DNA Ladder.  D) Cell surface expression of the Gal epitope 
by using IB4 Lectin-FITC.  The WT cells clearly have lectin binding, thus GGTA1 
expression.  All three CMAH/GGTA1 DKO pigs clearly don’t have lectin binding, thus 
are lacking GGTA1 expression.  Cells were imaged at 10 × magnification, with a 5 
second exposure.	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Decreased transcript level of H-D and Tn-related Genes in CMAH & GGTA1 DKO Pig 
Cells 
The Hanganutziu-Deicher antigen (H-D) plays a pivotal role in acute immune 
rejection of pig xenografts (Ezzelarab et al., 2005; Park et al., 2011; Park et al., 2012).  
Generally, H-D antigen families are classified as 2 different subfamilies; ST3Gal 
(ST3Gal1, ST3Gal2, ST3Gal3, ST3Gal4, ST3Gal5, and ST3Gal6) and ST6Gal (ST6Gal1 
and ST6Gal2), according to the carbohydrate linkages synthesized (Harduin-Lepers et al., 
2005). To normalize the mRNA level of WT-, CMAH biallelic KO-, and CMAH/GGTA1 
biallelic DKO-pigs, ACTB mRNA was used as an internal standard. After normalization 
with ACTB mRNA, ST3GAL1, ST3GAL3, ST3GAL4, ST6GAL1, and ST6GAL2 gene 
expression in CMAH/GGTA1 biallelic DKO-pigs were significantly down-regulated, 
whereas ST3GAL2 was up-regulated, compared to those of WT and CMAH biallelic KO 
pigs, respectively (Figure 9).  This observation suggested that down-regulated ST3GAL1, 
ST3GAL3, ST3GAL4, ST6GAL1, and ST6GAL2 in CMAH/GGTA1 biallelic DKO-pigs 
potentially should result in decreased Siaα2,3Galβ1,3GalNAc-R, 
Siaα2,3Galβ1,4GlcNAc-R and Siaα2,6Galβ1,4GlcNAc-R expression, but increased 
Siaα2,3Galβ1,3GalNAc-R, Sialyl Lew X: Siaα2,3Galβ1, 4(Fucα1,3)GalNAc-R, and 
Siaα2,4Galβ1,4GlcNAc-R expression, respectively, that act as an immune antigen within 
transplanted recipients.  Also, ST6GALNAC3 expression for Sialyl-Tn antigen, GALNT2, 
GALNT3, GALNT4 and GALNT7 expression for Tn antigen in biallelic CMAH KO pigs 
were significantly down-regulated compared with CMAH biallelic KO pigs (Figure 9). 
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A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*P<0.005, **P<0.0001, ***P<0.00001 
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B) 
 
 
 
Figure 9.   Sialyltransferase gene expression levels in control, biallelic CMAH KO, 
and biallelic CMAH and GGTA1 DKO pigs.  A) Comparison of sialyltransferase gene 
expression in control-, CMAH KO-, and CMAH/GGTA1 DKO-derived pig fibroblast cells 
by using real-time RT-PCR.  B) Quantification of real-time RT-PCR analysis in control-, 
CMAH KO-, and CMAH/GGTA1 DKO-pig fibroblast cells. All RT-PCR reactions were 
conducted in triplicate and normalized with pig actin mRNA.  Each of CMAH KO- and 
CMAH/GGTA1 DKO-pig relative values is presented as an n-fold expression difference 
compared to the control pig, which was set as 1. 
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Discussion 
 
 Gene targeting allows precise modifications to be made in cells for the functional 
analysis for the gene of interest.  However, the fairly low efficiency of traditional gene 
targeting has limited the utility of gene targeting in the study of gene function.  The 
application of custom nucleases has enabled new methods to edit the genomes in a 
variety of species.  To date, three different types of programmable nucleases, ZFNs (Kim 
et al., 1996), TALENs (Boch et al., 2009), and CRISPR/Cas9 (Jinek et al., 2012) have 
been used for genome editing.  These tools facilitate the induction of DSBs in a target-
specific manner.  Upon genomic breakage, cells can repair the damage through one of 
two major DNA repair systems, NHEJ or HR.  If the break is repaired by NHEJ, repaired 
sequences frequently harbor insertions or deletions.  The mechanism of HR enables a 
precise repair of the genomic break, but provides a much lower frequency (Capecchi, 
1989).  Traditional gene targeting approaches, which utilize HR machinery in the cell, 
have used targeting arms in the range of 1 – 8 kb in length of homology compared to the 
target locus (Hasty & Bradley, 1993).  However, successful HR has also been reported 
using less than 0.5 kb homologous arms (Hasty, Rivera-Perez, & Bradley, 1991).  In 
general, the length of contiguous sequence identity is the major determinant of HR 
efficiency (Waldman & Liskay, 1988).  In addition, Smih et al. (1995) demonstrated that 
gene targeting through HR could be stimulated by genomic DSBs introduced by a 
restriction enzyme.  Customized nucleases provide a means to generate DSB at specific 
locations within a genome, thereby increasing the efficiency of gene targeting.  Although 
these nucleases are used in genetic engineering, standards for donor DNA design are not 
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yet established.  Therefore we wanted to evaluate the effect of donor DNA length and 
nuclease-mediated gene targeting.  Here, we describe the disruption of two genes (CMAH 
and GGTA1) through ZFN- and TALEN-mediated gene targeting in pigs.  Since 
nucleases are being utilized in the genetic engineering of pigs, an increase in the 
efficiency of gene targeting will have a major impact for the production of genetically 
engineered pigs. 
 The primary goal of the projects was to generate CMAH/GGTA1 DKO cells/pigs 
utilizing nucleases and the secondary goal was to evaluate the effect of minimum 
homology length to direct HR after nuclease-mediated DSBs.  To illustrate the proof of 
concept that small repair template (donor DNA) can facilitate HR, we utilized a pair of 
functional ZFNs (Kwon et al., 2013) in conjunction with three different sizes of donor 
DNA to facilitate HR.  In our initial study, we employed an in vitro HR detection assay to 
determine the significance of the size of homology arms to the efficiency of HR.  We 
determined the HR frequency by using a PCR method.  Overall, we detected 
recombination events with all lengths of homology arms (as small as 35 bp and as long as 
125 bp); 125 bp arms resulted in 10 fold higher efficiency of HR than that of 35 bp 
(Figure 5).  Thus, our ZFN-CMAH results suggest that donor DNA with a minimum of 35 
bp of homology is able to successfully facilitate HR during ZFN-mediated gene targeting, 
but an increase in homology increased the targeting efficiency.  We also demonstrated 
that this strategy can be used to introduce specific mutations rather than just KO’s caused 
by ZFN-mediated NHEJ, but at a much lower frequency. 
 Given our ability to facilitate HR with small donor DNA in vitro, we chose to 
investigate the lengths of donor DNA and their effects with TALEN-mediated gene 
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targeting of the porcine GGTA1 gene.  In an attempt to determine the minimum length of 
homology utilizing TALEN-mediated gene targeting, we demonstrated that the addition 
of donor DNA increases the bi-allelic modifications when compared to TALEN-mediated 
gene targeting without donor DNA.  As our primary goal was to identify homozygous 
GGTA1 KO cells, GGTA1 null cells were counter-selected by using flow cytometry to 
detect the Gal deficient cells.  The introduction of any sized donor DNA resulted in a 
higher amount of bi-allelic modifications.  However, the modifications were point 
mutations.  The normal cellular repair pathway of NHEJ likely introduced these 
mutations.  
When comparing the two methods of nuclease-mediated gene targeting (ZFN vs. 
TALEN), the differences observed are likely due to: 1) experimental variation; 2) the 
higher fidelity of the PCR detection methods (ZFN experiment); and/or 3) the donor 
DNA may have an effect on the NHEJ pathway rather than through the HR repair 
mechanism (TALEN experiment).  In the ZFN/CMAH study we exclusively measured the 
efficiency of HR, while in the TALEN/GGTA1 experiments a lectin-based approach 
screened for the phenotypic changes of the Gal epitope after biallelic modifications to the 
GGTA1 gene.  Even though our ZFN/CMAH results demonstrated that HR was occurring, 
HR did not occur and create biallelic modifications in the TALEN/GGTA1 results.  
However, we did observe an increase in GGTA1-null cells when both donor DNA and 
TALENs were applied.  There are two potential explanations for this.  The first is that our 
study only assessed for bi-allelic modifications of GGAT1 (KO cells); we may have 
unintentionally created a bias to observe cells that were modified by the NHEJ pathway.  
The second is that the donor DNA may actually play a role in NHEJ and not just HR.  As 
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previously reported (Kwon et al., 2013; Whitworth et al., 2014), we have observed an 
increase in targeting efficiency in the presence of donor DNA, but NHEJ and not HR is 
observed.  A potential explanation is that HR and NHEJ pathways are not independent, 
but can, or potentially, do act together in the repair process. 
 The Gal epitope has been identified as the primary target for natural human 
antibodies, and the successful KO of the GGTA1 gene was an important step toward 
overcoming the major immunological barrier in pig-to-human xenotransplantation (Dai et 
al., 2002; Lai et al., 2002).  The CMAH gene has also been identified as another potential 
major xeno-antigen (Basnet et al., 2010; Tahara et al., 2010).  As previously reported by 
Kwon et al. (2013), the ablation of the CMAH gene resulted in the reduction of 
expression of Hanganutziu-Deicher (H-D), Thomsen-Friedenreich (TF), Tn, and sialyl-
Tn.  It is known that all four gene families play a pivotal role in acute immune rejection 
of pig xenografts (Ezzelarab et al., 2005).  In this study, we were able to demonstrate that 
the gene expression in most instances was drastically reduced in the CMAH/GGTA1 
DKO cells compared to wild-type cells and even further down regulated compared to 
CMAH null cells. 
 In conclusion, the methods described in this study allow for an approach to 
generate KO cells and pigs with an increased targeting efficiency.  The gene editing 
methods can be applied to other genes as well as other mammalian systems.  Additionally, 
we predict that the utility of the CMAH/GGTA1 DKO pigs can be a valuable source for 
the study of pig-to-human xenotransplantation. 
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CHAPTER IV 
 
 
CRISPR/CAS9-MEDIATED GENE STACKING/GENE TARGETING 
PRODUCES SWINE WITH HIGH UBIQUITOUS EXPRESSION OF HUMAN 
CD55 AND HIGH ENDOTHELIAL-SPECIFIC EXPRESSION OF HUMAN CD39 
 
 
 
Abstract 
 
Genetic engineering facilitates heritable modification of target genomes.  
Modifications can be site-specific or random.  Though inefficient, homologous 
recombination allows for precise genome modification.  Random integration is more 
efficient but the orientation and location of the introduced DNA is not regulated.  Thus, 
an efficient method for site-specific integration would have utility.  Double strand break 
of the target sequence is often a rate-limiting step of homologous recombination.  Gene-
editing techniques can now be designed to create target-specific cleavage and facilitate 
the insertion of exogenous DNA through homologous recombination.  The specific 
objective of this project was to utilize the CRISPR/Cas9 system to direct single-copy 
integration of exogenous DNA into the target site and evaluate the frequency of insertion.  
To evaluate the feasibility of this strategy, we inserted two transgenes (Hygromycin and 
hCD39) into a previously modified GGTA1 locus (GGTA1 KO harboring a Neomycin 
cassette and a hCD55 transgene cassette, GGTA1IRES-Neo; CAG-hCD55/+).  We observed an 
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increase in gene targeting efficiency from 8.7% to 37.8% when using the CRISPR/Cas9 
system over traditional methods.  In addition, we inserted four transgenes (Neomycin, 
Hygromycin, hCD39, and hCD55) into wild-type cells to disrupt the GGTA1 locus in a 
single step.  Here, we observed an increase in average gene targeting efficiency from 
2.2% to 40.0% when using the CRISPR/Cas9 system.  These studies demonstrate that the 
CRISPR/Cas9 system is an efficient method to facilitate the addition of multiple 
transgenes.  The genetically engineered fibroblasts are compatible with somatic cell 
nuclear transfer as a day 45 fetus and 2 live piglets were generated. 
 
 
Introduction 
 
Genetic engineering technologies of swine have advanced to a point where 
imagination and resources are the only limitations.  As the requirement for genetic 
modifications become more complex, a need to genetically link multiple transgenes has 
become apparent.  In other words, it has become logistically and economically important 
to ensure that multiple transgenes are inherited together.  This consideration is 
particularly important in regard to maintenance and propagation of genetic lines that 
harbor multiple genetic modifications.  The propagation and maintenance of animals with 
an increasing number of modifications warrants a large degree of complexity to yield the 
desired genotype of all modifications.  
We have chosen to apply a step-wise strategy that places each new transgene 
adjacent to the previous transgene(s) such that each modification becomes genetically 
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linked to previous modifications.  In the end, transmission of the desired genotype in a 
wild-type cross would result in half the progeny.  Upon breeding of two 
heterozygous/hemizygous animals, one fourth of the progeny would be expected to be 
homozygous.  The genetics follows normal Mendelian inheritance and simple breeding 
programs can be implemented.   
The objective of this project was to develop a strategy that would allow for the 
sequential addition of multiple transgenes while ensuring the genetic linkage of the 
transgenes.  In this study we utilized the Clustered Regularly Interspaced Short 
Palindromic Repeats/Cas9 (CRISPR/Cas9) system to facilitate a double strand break and 
direct integration of multiple genetically linked transgenes at an improved frequency.  
The ability to “knockin” additional transgenes adjacent to previously targeted genes 
would result in the end goal of generating transgenic pigs that have multiple transgenes 
that are genetically linked. 
 Gene targeting by homologous recombination (HR) allows for precise 
modifications to the target genome (Capecchi, 1989).  In cells, HR a natural cellular 
process used to repair DNA double-strand breaks (DSBs).  It has also been shown that 
target genome breakage is the rate-limiting step in HR (Song et al., 1985; Hasty & 
Bradley, 1993; 1994; Rouet et al., 1994; Choulika et al., 1995).  The CRISPR/Cas9 
system includes a nuclease guided by a short RNA that pairs with the target DNA.  Once 
paired, the Cas9 enzyme cleaves both strands of DNA creating a DSB (Jinek et al., 2012).  
The DSB can be repaired by non-homologous end joining (NHEJ) to generate random 
mutations or can be repaired using exogenous template DNA by HR.   
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These studies were designed to facilitate animal models for pig-to-human 
xenotransplantation, as multiple modifications are likely required to overcome 
immunological barriers (Cooper et al., 2012).  Due to the lack of viable human donor 
organs, the possibility of utilizing animal tissues/organs has been considered a possible 
solution.  Pig organs are seen as a potential resource for xenotransplantation as pigs are 
anatomically and physiologically similar to humans (Cooper et al., 1991; Sachs, 1994; 
Cooper et al., 2002; Cooper, 2012).  A major xenoantigen responsible for tissue rejection 
is the alpha 1,3-linked terminal galactose (Gal) epitope (Galili et al., 1988; Cooper et al., 
1993).  Humans have preformed antibodies against the Gal epitope, which initiates 
hyperacute rejection (HAR) of porcine cells that are naturally abundant in the epitope 
(Lambrigts et al., 1998).  Thus, the absence of Gal expression appears to be one of the 
elements essential for successful xenotransplantation.  The alpha 1,3- 
galactosyltransferase (GGTA1) gene encodes the enzyme responsible for deposition of 
the Gal epitope (Galili et al., 1988; Cooper et al., 1993).  Several groups have 
demonstrated the ability to disrupt the GGTA1 gene (Denning et al., 2001; Dai et al., 
2002; Harrison et al., 2002; Lai et al., 2002; Jin et al., 2003; Takahagi et al., 2005).  
However, the absence of the Gal epitope is not the only element essential for 
xenotransplantation.  Additional genes regulating immune function are likely required in 
conjunction to the disruption of the GGTA1 gene (Ramsoondar et al., 2003; Fujimura et 
al., 2004; Diaz-Roman et al., 2006).   
In an attempt to generate a multi-transgenic xenotransplantation pig, we have 
developed a strategy that combines gene stacking with gene targeting such that a series of 
transgenes can be placed within the disrupted GGTA1 locus.  To produce 
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previously targeted the GGTA1 locus through homologous recombination with a targeting 
vector that contains a floxed neomycin selectable marker (NeoR), a transgene that codes 
for the human protein CD55, and a PhiC31 attB site (Figure 11) (Beaton et al., 2013).  To 
facilitate the addition of subsequent transgenes in a sequential manner, we chose to use a 
gene-stacking system that utilizes the CRISPR/Cas9 system to generate a double strand 
break in the genomic DNA to increase the efficiency of homology directed repair of a 
gene targeting vector (Figure 11).  In the first set of experiments, we chose to repurpose 
the unique PhiC31 attB as a target sequence for the CRISPR/Cas9 system and in the 
presence of a targeting vector we were able to achieve targeted insertion of two additional 
genes (Hygromycin and hCD39).  Further, we implemented a supplementary strategy that 
employs the CRISPR/Cas9 system to simultaneously insert four exogenous genes 
(Neomycin, Hygromycin, hCD55, hCD39) into the GGTA1 locus (Figure 12).  In 
addition to the insertion capabilities of our targeted insertion strategies, we have 
engineered the use of an excision-favoring recombinase system, Cre/loxP, to remove 
DNA that has become superfluous after integration.  
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Figure 10. Graphical representation of PhiC31 attB specific CRISPR/Cas9-
mediated gene targeting.  A.) Top diagram illustrates wild-type GGTA1 locus.  B.) The 
middle diagram illustrates a previously targeted GGTA1 locus.  C.) The lower diagram 
illustrates a pBB57-targeted allele after the PhiC31 attB CRISPR sgRNA facilitated the 
targeted insertion of pBB57.  The homologous sequence in the pBB57-targeting vector 
was used to promote homologous recombination (5' homologous arm: 5' GGTA1, IRES-
NeoR and 3' homologous arm: CAG-hCD55, 3' GGTA1).  Short arrows along with their 
respective names; indicate the position of the primers used for the PCR assays.  The PCR 
assays were designed to amplify only targeting events.   
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Figure 11. Graphical representation of GGTA1 EcoRV specific CRISPR/Cas9-
mediated gene targeting.  A.) Top diagram illustrates wild-type GGTA1 locus.  B.) The 
lower diagram illustrates a pBB57-targeted allele after the GGTA1 EcoRV CRISPR 
sgRNA facilitated the targeted insertion of pBB57.  The homologous sequence in the 
pBB57-targeting vector was used to promote homologous recombination (5' homologous 
arm: 5' GGTA1 and the 3' homologous arm: 3' GGTA1).  Short arrows along with their 
respective names; indicate the position of the primers used for the PCR assays.  The PCR 
assays were designed to amplify only targeting events.   
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Materials And Methods 
 
All restriction enzymes used were sourced from New England Biolabs (NEB) unless 
otherwise noted. 
 
Targeting Vector Construction 
 A single targeting construct, pBB57, was assembled from several intermediate 
plasmids.  The pBB57 targeting vector included several components: 1) a 6,641 bp 
GGTA1 genomic fragment (5' Arm: 4,822 bp; 3' Arm: 1,819 bp); 2) a mammalian codon 
optimized neomycin resistance (NeoR) cassette, where expression stems from a promoter 
trap of the porcine GGTA1 gene through the use of an internal ribosome entry site (IRES), 
flanked by loxP sites; 3) a hygromycin resistance (HygroR) cassette, flanked by loxP sites; 
4) an R4 Phage attachment B (attB) site; 5) a human CD39 (hCD39) cassette with 
endothelial specific expression, where expression is driven by a murine Tie2 promoter 
and Tie2 enhancer element; and 6) a human CD55 (hCD55) cassette with ubiquitous 
expression, where expression is driven by the CAG promoter (Figures 11 and 12). 
Previously, a targeting vector (pBB13) was generated with a 6,641 bp GGTA1 
genomic fragment and a 5,740 bp loxP-IRES-mNeoR-loxP-CAG/hCD55-PhiC1 attB-
SV40 poly (A) cassette inserted into the unique EcoRV site in exon 9 of GGTA1 (Beaton 
et al., 2013).  A series of modifications were made to pBB13, a multiple cloning region 
was added and the PhiC31 attB site was removed and inserted between the second loxP 
site and the CAG promoter, the resulting plasmid was named pBB18 (2014).  The utility 
of relocating the attB site will be advantageous to future additions of transgenes and the 
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ability to remove superfluous DNA, i.e. selectable markers or E. coli backbone 
components, without disrupting or destroying previously added transgenes.   
The HygroR cassette, R4 attB site, and an endothelial specific hCD39 transgene 
cassette were sourced from commercial and lab-constructed plasmids.  The hCD39 was 
isolated from cDNA Clone: LIFESEQ2862692 (Open Biosystems, Catalog Number: 
IHS1380-212907370, Accession: NM_001776).  A small intron, 81 bp, was amplified 
from porcine CD163 using the primer pair CD163 intronL 5' 
GAAAATGacGcGTcCTGCAGgtgagaatcagtgaccaacctatgaa and CD163 intronR 5' 
ccaggcGAATTcACCACTCCctgcaaagaggaaataaaac.  The small intron was digested with 
MluI and EcoRI and directionally cloned into the unique MluI and EcoRI sites in clone 
LIFESEQ2862692, generating plasmid pBB30.  To provide endothelial cell-specific 
expression of hCD39, the hCD39 and CD163 intron were added to a plasmid containing 
the murine Tie2 promoter (2.1 kb) and regulatory region (10.4 kb), as previously defined 
(Schlaeger et al., 1997).  A 2,601 bp SbfI/XbaI fragment, containing the CD163 intron 
and hCD39 cDNA, were isolated from pBB30 and directionally cloned into a previously 
modified Tie2 promoter/Tie2 enhancer plasmid (Suvorava & Kojda, 2009; Whyte et al., 
2011) (a generous gift of G. Kojda für Pharmakologie und Klinische Pharmakologie, 
Heinrich-Heine-Universität, Dusseldorf, Germany) at the compatible SbfI/NheI sites, 
producing the plasmid pBB31.  For the addition of the R4 attB site and the HygroR 
cassette, a 15,465 bp AbsI/NotI fragment harboring the hCD39 transgene cassette was 
isolated from pBB31 and directionally cloned into pBB53 (Beaton & Wells, 2014) at the 
compatible AbsI/NotI sites, producing the plasmid pBB55.  A 17,615 bp SbfI fragment 
from pBB55 was cloned into pBB18’s SbfI site to generate pBB57.  The final resulting 
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plasmid was 33,355 bp in total size.  The targeting vector was linearized using BstBI 
prior to transfection. 
 
Design and Construction of CRISPR/gRNA Expression Vectors 
 For the CRISPR/Cas9 system, target guide sequences for single guide RNAs 
(sgRNA) were designed to precede the Streptococcus pyogenes protospacer adjacent 
motif (PAM) as previously described (Jinek et al., 2012; Mali et al., 2013).  Guide 
sequences were evaluated for RNA structure (Zuker, 2003) and potential off-target 
cleavage effects using Sus scrofa (pig) NCBI Nucleotide BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch&BLAST_SPEC=O
GP__9823__10718).  The sequences of the sgRNAs were designed to regions of the 
engineered PhiC31 attB site and to the EcoRV region in exon 9 of GGTA1.   
To target PhiC31 attB, three sgRNAs were designed.  PhiC31 attB # 1 (pBB67) 
and PhiC31 attB # 2 (pBB68) sgRNAs are on the antisense strand.  The PhiC31 attB # 3 
(pBB69) sgRNA is on the sense strand.  The PhiC31 attB sgRNA sequences, including 
the PAM sequence are: PhiC31 attB # 1 (pBB67) 5'-
TCGCGCCCGGGGAGCCCAAGGG-3', PhiC31 attB # 2 (pBB68) 5'-
GTACAAGTCGACTTCGCGCCCGG-3', PhiC31 attB # 3 (pBB69) 5'-
GCATGTCGACCACTTAATTAAGG-3'.  To target GGTA1, a single sgRNA was 
designed to target the sense strand.  The GGTA1 sgRNA sequence is 5'-
ATCTGCAAATACATACTTCATGG-3'.  For each target sgRNA, following the Zhang 
laboratory protocol (http://www.genome-engineering.org/crispr/wp-
content/uploads/2014/05/CRISPR-Reagent-Description-Rev20140509.pdf) a pair of 
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oligonucleotides (Table 8) were annealed and cloned into pX330 (Addgene plasmid 
#42230) (Cong et al., 2013).  The pX330 vector is a vector that contains two expression 
cassettes, a human codon-optimized Streptococcus pyogenes Cas9 and a chimeric sgRNA.  
The resulting expression vectors were named pBB67, pBB68, pBB69, and pBB71.  
pBB67 – 69 are specific to PhiC31 attB and pBB71 is specific to GGTA1. 
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Table 8. Designed sgRNAs.  Forward and Reverse primers were annealed 
following the Zhang protocol. 
 
sgRNA Primers Sequence (5' – 3') 
Forward – PhiC31 attB # 1 (pBB67) caccgTCGCGCCCGGGGAGCCCAA 
Reverse – PhiC31 attB # 1 (pBB67) aaacTTGGGCTCCCCGGGCGCGAc 
Forward – PhiC31 attB # 2 (pBB68) caccGTACAAGTCGACTTCGCGCC 
Reverse – PhiC31 attB # 2 (pBB68) aaacGGCGCGAAGTCGACTTGTAC 
Forward – PhiC31 attB # 3 (pBB69) caccGCATGTCGACCACTTAATTA 
Reverse – PhiC31 attB # 3 (pBB69) aaacTAATTAAGTGGTCGACATGC 
Forward – GGTA1 E9 (pBB71) caccgATCTGCAAATACATACTTCA 
Reverse – GGTA1 E9 (pBB71) aaacTGAAGTATGTATTTGCAGATc 
 
	   97 
Preparation of Porcine Fibroblast Cells and Culture Conditions 
For the CRISPR/Cas9-mediated gene stacking/targeted insertion experiments, tail 
tissue was collected and minced from a male piglet (NSRRC:0037, National Swine 
Resource and Research Center , University of Missouri), GGTA1IRES-Neo; CAG-hCD55/+	  
Minnesota Miniature Pig genetic background (Beaton et al., 2013).  The minced tissue 
was washed and cultured in complete medium (Dulbecco’s modified Eagle’s medium 
(DMEM) containing 2.77 mM glucose, 1.99 mM L-glutamine, and 0.5 mM sodium 
pyruvate (Cellgro, Manassas, VA), supplemented with 1 mM L-alanyl-L-glutamine 
(Cellgro) and 15% fetal bovine serum (FBS) (HyClone), at 38.5°C in 5.5% CO2, 5% O2, 
and 89.5% N2 balanced humidified air.  After two passages, cultured cells were harvested 
and frozen at -80°C in aliquots of 90% FBS with 10% dimethyl sulfide (DMSO, Sigma) 
and stored in liquid nitrogen. 
For the CRISPR/Cas9-mediated gene targeting experiments, wild-type male and 
female fetal fibroblast cell lines of the Minnesota Miniature Pig genetic background 
(NSRRC:0005) were established from day 35 and day 45 fetal collections.  Fetuses were 
collected into individual 50 mL conical bottom centrifuge tubes.  The fetuses were 
washed twice in Dulbecco’s PBS (Invitrogen) to remove excess debris, once in 70 % 
ethanol to disinfect, and once more in Dulbecco’s PBS to remove excess ethanol.  The 
head and viscera were removed; the remaining tissue was minced and cultured in 
complete medium.  After a single passage, the cultured cells were harvested and frozen at 
-80°C in aliquots of 90% FBS with 10% DMSO and stored in liquid nitrogen.  Four male 
and three female lines were established and used in the experiments.   
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Transfection of Targeting Vector and PhiC31/attB CRISPR Expression Vectors 
Transfection conditions were as previously reported (Beaton & Wells, 2014).  As 
there is not an optimized protocol to perform homology directed targeting in porcine 
somatic cells, three series of transfections were conducted.  To evaluate the molecular 
ratio of Donor DNA to sgRNA/Cas9 expression vector, varying amounts of Donor DNA 
and sgRNA/Cas9 expression vectors were tested.  The transfections were performed in 
male passage three porcine ear and tail fibroblasts, GGTA1IRES-Neo; PhiC31 attB; CAG-hCD55/+	  
(NSRRC:0037).  The fibroblast cells were cultured for 72 hours and grown to 70 – 90% 
confluency in complete medium at 38.5°C in 5.5% CO2, 5% O2, and 89.5% N2 balanced 
humidified air.  Fibroblasts were harvested by trypsinization and were re-suspended at a 
density of 1 X 106 cells/mL in a modified electroporation media (25% OptiMEM 
(Invitrogen) + 75% buffered KCl (Sigma, St. Louis, MO; 135mM KCl, 15 mM Tris, 11.3 
mM BES, 3.7 mM PIPES, pH 7.3).  Two hundred µL of the cell suspension (200,00 
cells) and DNA BstBI linearized targeting vector DNA, pBB57; supercoiled sgRNA/Cas9 
expression vectors - pBB67, pBB68, pBB69) were placed in a 2 mM electroporation 
cuvette and the cells were electroporated by using 250 volts X 3 pulses for 1 milli-
second/pulse by using a square wave generator (BTX Electro-cell Manipulator 200, San 
Diego, CA).  Electroporated cells were cultured in complete medium in twenty 100 mm 
tissue culture plates (~10,000 cells/plate).  Twenty-four hours after culture, cells were 
administered Hygromycin B (300mg/L, Invitrogen) and cultured for 13 more days.  
HygroR colonies were then harvested by using cloning cylinders and screened by PCR.   
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Transfection of Targeting Vector and GGTA1 CRISPR Expression Vectors 
 Based upon the results for the gene stacking/targeting into the GGTA1 
PhiC31attB site, we chose to explore the possibility to target the GGTA1 gene by adding 
all four transgenes (NeoR, HygroR, hCD39, and hCD55) into the GGTA1 locus.  In 
addition, based upon our results that an increasing amount of sgRNA/Cas9 expression 
vector yielded higher targeting (Figure 13), we chose to further explore the ratios of 
donor DNA to sgRNA/Cas9 expression vector.  The same transfection methods are used 
as described above.  For this set of experiments, nine series of transfections were 
performed by using various ratios of donor DNA (pBB57) to a sgRNA/Cas9 vector 
(pBB71), which targets exon 9 of GGTA1, in male and female wild-type fetal fibroblast 
cells of the Minnesota Miniature pig genetic background.  
 
Screening and Analysis of Knock-out Cells and Pigs 
Thirteen days after selection, G418 resistant (G418R) or Hygromycin B resistant 
(HygroBR) colonies were harvested by using cloning cylinders and screened by PCR.  
Two thirds of harvested cells were transferred to a single well of a 24-well tissue culture 
plate for expansion under the same G418R /HygroBR medium and one third of cells 
isolated were used for PCR analysis of targeted clones.  Approximately 1,000 cells (1/3 
of a colony) were re-suspended in 5 µL of a lysis buffer (40mM Tris, pH 8.9; 0.9% 
Triton X-100; 0.9% Nonidet P-40; 0.4 mg/mL proteinase K, (Sigma)), incubated at 65°C 
for 15 minutes to disrupt the cells, and then heated to 95°C for 10 minutes to inactivate 
the proteinase K.   
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Three primer sets were used for PCR analysis by using the TaKaRa LA system 
(Takara Bio Inc., Japan) and are illustrated in Figures 11 and 12.  The first primer pair 
flanked the upstream (5') homology arm and resulted in a PCR product of 11.2 kb from a 
targeted locus.  One µl of cell lysate was used as template in a 25 µl reaction volume with 
the following parameters: 94°C for 1 minute, followed by 30 cycles of 30 seconds at 
94°C, 30 seconds at 62°C, and 6.5 minutes increasing 13 seconds/cycle at 68°C, with a 
final extension of 5 minutes at 72°C.  The upstream assay primers were: GLR_L1 5'-
GGAGAGGAGAATGGTGTCACAGGGCCA-3' and Tie2_R1 5'-
AACTTTGCGACTTCCCGCTCGCATGG-3'.  The second primer pair flanked the 
downstream (3') homology arm and produced a band of 3.8 kb from a targeted locus.  
One µl of cell lysate was used as template in a 25 µl reaction volume with the following 
parameters: 94°C for 1 minute, followed by 30 cycles of 30 seconds at 94°C, 30 seconds 
at 62°C, and 2.5 minutes increasing 5 seconds/cycle at 68°C, with a final extension of 5 
minutes at 72°C.  The downstream assay primers were: GSR_L1 5'-
AGTGCCGTCCAGGTTACAGAAGAGAACC-3' and GLR_R1 5'-
GAGTAGGAGGCCCAGGGAAACAGTAGAG-3'.  The third primer pair (previously 
described, GLR_L1 and GLR_R1) was used to evaluate the native GGTA1 locus, if there 
was a modification to both GGTA1 allele then the long range PCR assay would not be as 
predicted.  The primer pair flanks the upstream (5') and downstream (3') homology arms 
of the targeting vector.  The resulting PCR product would only generate a wild-type PCR 
product of 7.2 kb.  One µl of cell lysate was used as template in a 25 µl reaction volume 
with the following parameters: 94°C for 1 minute, followed by 30 cycles of 30 seconds at 
94°C, 30 seconds at 62°C, and 6.25 minutes increasing 15 seconds/cycle at 68°C, with a 
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final extension of 13 minutes at 72°C.  For later use in SCNT, positive colonies were 
expanded and upon confluency were frozen at -80 °C in aliquots of FBS with 10% 
DMSO and transitioned into liquid nitrogen for long-term preservation. 
 
Cre/loxP-Mediated Excision of Selectable Markers 
 The genes encoding the selectable markers were introduced into the genome to 
aid in the selection process by isolate cells that contain the desired stacked/targeted 
genotype.  For the addition of future modifications, selectable markers may be required to 
aid in the isolation of those modifications.  Therefore, the removal of the selectable 
marker allows recycling of selectable markers for future modifications.  Not only did we 
want to remove the selectable markers, but we wanted to eliminate a cloning step by 
performing more than one modification prior to somatic cell nuclear transfer (SCNT).  In 
the normal cloning process, a cloned animal or fetus is generated with a particular 
modification and then additional modifications are applied to the cells from the cloned 
animal.  Our strategy implements multiple modifications prior to SCNT.  Once we have 
isolated a cell population that contains the desired modifications (NeoR, HygroR, hCD39, 
and hCD55), then the removal of the selectable markers (NeoR and HygroR) will be 
facilitated by the Cre/loxP system.  
 To remove the selectable markers, 3 – 7 days prior to SCNT cells were transiently 
transfected with a Cre expression vector, pCAG:Cre-GFP (Addgene plasmid 
13776;(Matsuda & Cepko, 2007)). The lipid-based transfection protocol and conditions 
used were as previously described (Beaton & Wells, 2014).  In a 24 well plate, ~15,000 – 
20,000 cells were transfected with 750 ng pCAG:Cre-GFP and 2 µL FuGENE HD 
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(Promega, Madison, WI).  The cells were transfected in complete medium, as described 
above, for 48 hours.  After 48 hours, the cells were cultured in fresh complete medium to 
either be cyro-preserved or used for SCNT.  Evaluation of Cre-mediated excision was 
determined on live piglets, we expected ~80% of the cells used for SCNT to have 
undergone Cre-excision (Beaton & Wells, 2014). 
 
Somatic Cell Nuclear Transfer (SCNT) 
For SCNT, sow-derived oocytes were purchased from ART (Madison, WI).  
Cumulous oocyte complexes were aspirated from sow ovaries and then shipped overnight 
in maturation medium (TCM199 with 2.9 mM Hepes, 5 mg/mL insulin, 10 ng/mL EGF, 
0.5 mg/mL p-FSH, 0.91 mM pyruvate, 0.5 mM cysteine, 10% porcine follicular fluid, 25 
ng/mL gentamicin).  Upon arrival, the oocytes were transferred into fresh medium and 
cultured for additional 20 – 24 hours.  After a total of 40 – 42 hours of maturation, 
cumulus cells were removed from the oocytes by vortexing for 3 min in the presence of 
0.1% hyaluronidase.  The denuded oocytes were manipulated in manipulation medium 
that consisted of Hepes-buffered TCM-199, 0.3% BSA, and 7.5 µg/ml of cytochalasin B 
(CB).  The polar body along with a portion of the adjacent cytoplasm was removed, and a 
donor cell was placed in the perivitelline space as previously described (Lai & Prather, 
2003).  The reconstructed embryos were then fused and activated in fusion medium (0.3 
M mannitol, 0.1 mM CaCl2, 0.1 mM MgCl2, 0.5 mM Hepes) by using two DC pulses (1-
sec interval) at 1.2 kV/cm for 30 µsec (by using a BTX Electro Cell Manipulator, 
Harvard Apparatus, Holliston, MA).  Embryos were then incubated in PZM3 (Yoshioka 
et al., 2002), for 14 – 16 hours.  The next day, the SCNT embryos were surgically 
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transferred into the ampullary-isthmic junction of a surrogate at 0 or 1 day after observed 
estrus.  The surrogates were checked for pregnancy by ultrasound examination around 
day 30.  The cloned fetus was collected on day 45 of gestation.  The cloned piglets were 
delivered by cesarean section on day 116 or 117 of gestation. 
 
RNA Isolation, Reverse Transcriptase, and PCR Analysis of hCD39 Expression 
 RNA was extracted from transgenic (pBB57 targeted into GGTA1) and wild-type 
piglets.  Total RNA was isolated from xenotransplantation significant organs (heart, liver, 
lung, kidney, pancreas) and unrelated tissues (tail, spleen, and umbilical) by using STAT-
60 RNA extraction reagent (Tel-Test, Inc., Friendswood, TX).  The extracted RNAs were 
treated with RNase-Free DNase (Qiagen, Valencia, CA) at room temperature according 
to the manufacturer’s recommendations.  The DNA-free RNA samples were quantified 
and analyzed for quality.  Two micrograms of RNA from each sample were reverse 
transcribed by using an oligo-dT primer and PrimeScript™ Reverse Transcriptase 
(TaKaRa, Japan) at 42°C for 1 hour. 
 Oligonucleotides for PCR on the cDNA were designed to span the engineered 
intron (Figure 16), hCD39_5' UTR_L1: 5'-TCGCAAAGTTGTGAGTTGTTG-3' and 
hCD39_R3: 5'-AAGCCAAGGATGGCTAGGAT-3'.  Oligonucleotides were also 
designed for a control gene in swine, GAPDH (glyceraldehyde 3-phosphate 
dehydrogenase), GAPDH_L1: 5'-GCAAAGTGGACATTGTCGCCATCA-3' and 
GAPDH_R1: 5'-AGCTTCCCATTCTCAGCCTTGACT-3'.  PCR was performed by 
using a mixture of AmpliTaq Gold® 360 DNA Polymerase system (Applied Biosystems, 
CA) and 0.5 µL of cDNA.  The PCR parameters were: 94°C for 2 minutes, followed by 
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40 cycles of 15 seconds at 94°C, 30 seconds at 60°C, and 1 minute at 72°C, with a final 
extension of 1 minute at 72°C. 
 
Characterization of hCD55 and hCD39 Ectopic Expression 
Xenotransplantation significant organs (heart, kidney, liver, lung, and pancreas) 
from transgenic piglets and diagnostic tissues (tail and umbilical) from transgenic and 
wild-type piglets were harvested and frozen in tissue freezing media (American 
MasterTech, CA).  Immunohistochemistry was carried out following general 
immunohistochemistry procedures on 5-micron thick sections fixed with ice-cold acetone.  
The tissue sections were reacted with primary mouse monoclonal antibodies against 
human CD55 (Clone: IA10, BD Biosciences) and human CD39 (Clone: BU61, Ancell). 
 
 
Results 
 
CRISPR/Cas9-Mediated Gene Stacking/Knock-in into PhiC31 attB 
 A series of experiments were performed to evaluate the efficiency of the 
CRISPR/Cas9 system by targeted insertion into a PhiC31 attB site.  The PhiC31 attB site 
was previously inserted into one allele of the GGTA1 gene and now served as a unique 
sequence that sgRNAs were designed to target.  The first experiment was to evaluate the 
effects on targeting efficiency if a single sgRNA or a combination of three sgRNAs was 
used in the presence of a targeting vector (pBB57).  When targeting vector DNA 
(pBB57) was kept constant and the sgRNA vector was kept constant, all four treatments 
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(pBB67 sgRNA, pBB68 sgRNA, pBB69 sgRNA, and all three sgRNAs) resulted in an 
increase of targeting at the PhiC31 location compared to targeting vector alone (Figure 
13).  In particular, any treatment that included the pBB67 sgRNA resulted in the highest 
targeting efficiency.  Thus, the subsequent set of experiments utilized only the pBB67 
sgRNA vector.  The second and third experiments were designed to evaluate and 
determine the optimum ratio/amount of donor targeting vector DNA and Cas9/sgRNA 
DNA.  If the total amount of DNA transfected was kept constant (a total of 3.5 µg), but 
the ratios of targeting vector DNA to Cas9/sgRNA DNA were changed (1:0, 5:1, 3:1, 1:1, 
1:3, 1:5), the targeting efficiency increased in the presence of higher amounts of 
Cas9/sgRNA DNA (Figure 13).  This observation led to the conclusion that higher 
amounts of Cas9/sgRNA DNA facilitate an increase in targeting.  To further evaluate this 
observation, we kept the targeting vector DNA constant (2.0 µg) and increased the 
amount of Cas9/sgRNA DNA, thus increasing the ratio of the two DNAs (1:0, 5:1, 3:1, 
1:1, 1:3, 1:5, 1:10).  The combined results demonstrate a higher targeting efficiency in the 
presence of more Cas9/sgRNA DNA and a constant amount of targeting vector DNA 
(Figure 13). 
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Figure 12. CRISPR/Cas9-Mediated Gene Stacking/Targeting into the unique 
PhiC31 attB previously targeted into the GGTA1 locus.   
A) Gene targeting the PhiC31 attB site located within the GGTA1 locus, testing different 
sgRNAs. The total application of DNA introduced was kept constant, 3.5 µg.   
B) Gene targeting the PhiC31 attB site with a single Cas9/sgRNA (pBB67 sgRNA) 
where the total amount of DNA being transfected was constant, but the ratios of targeting 
vector DNA to sgRNA DNA was varied.   
C) Gene targeting the PhiC31 attB site with a single sgRNA (pBB67 sgRNA) where the 
targeting vector DNA was kept constant, but the amounts of sgRNA DNA were varied to 
create different ratios of targeting vector DNA to sgRNA DNA.   
**In all panels, the data represents the percentage of gene targeting/integration at the 
target PhiC31 attB location.  Varying ratios of targeting vector DNA to Cas9/sgRNA 
expression vector was calculated per molecule. 
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CRISPR/Cas9-Mediated Gene Targeting into GGTA1 
To further optimize CRISPR/Cas9-mediated gene targeting and attempt to knock-
in 4 transgenes into a single locus in one step, various ratios of targeting vector to 
Cas9/sgRNA expression vector were transfected into wild-type porcine fibroblast cells.  
A single Cas9/sgRNA expression vector, pBB71, that specifically targets exon 9 of 
GGTA1 was used at varying concentrations of DNA in combination with a targeting 
vector, pBB57.  The targeting vector DNA was constant throughout the experiment, with 
different amounts of Cas9/sgRNA DNA to yield the following ratios; 1:0 (no 
Cas9/sgRNA control to compare to baseline targeting efficiencies), 3:1, 1:1, 1:3, 1:5, 
1:10, and 1:20.  The results from a total of 63 transfections (9 replicates) demonstrate that 
the addition of a Cas9/sgRNA expression in the target region of the targeting vector aids 
in CRISPR/Cas9-mediated gene targeting (Figure 14).  To test if there was a statistical 
significance across the entire dataset, a pairwise Chi-squared analysis was performed and 
showed significance at p = 0.001.  To test between treatment means, count data were 
analyzed by using the Student’s T-Test.  Based upon our gene targeting results, a ratio of 
1:3 – 1:10 would be an optimum ratio range for targeting vector DNA to Cas9/sgRNA 
expression vector DNA. 
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Figure 13.   CRISPR/Cas9-Mediated Gene Targeting the unique the EcoRV site 
on exon 9 of the GGTA1 locus.  
Gene targeting GGTA1 with a single Cas9/sgRNA expression vector (pBB71) where the 
targeting vector DNA was kept constant and the amounts of Cas9/sgRNA DNA were 
varied to create different ratios of targeting vector DNA to sgRNA DNA.  The data 
represents the gene targeting efficiency.  Varying ratios of targeting vector DNA to 
Cas9/sgRNA expression vector was calculated per molecule. 
Student T-test p <0.05.  * Significance was found when count data was compared to 1:0 
ratio.  # Significance was found when count data was compared to 3:1 ratio.  + 
Significance was found when count data was compared to 1:20 ratio. 
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Production of Gene-Stacked / Gene-Targeted Fetus and Targeted Pigs Through SCNT  
To confirm that the gene-stacked colonies could generate live offspring via SCNT, 
a pool of cells from different clones were used in three rounds of SCNT (Table 9).  One 
of the three recipients became pregnant; the pregnancy was terminated at day 45 to 
collect fetuses, a single fetus was recovered.   
To confirm that the gene-targeted colonies could generate live offspring via 
SCNT, a pool of cells from different male and female clones were used in 6 rounds of 
SCNT (Table 10).  Prior to SCNT, the cells were transiently transfected with the Cre 
recombinase to cre-excise the selectable markers, as they will not be desired for future 
use and we were attempting to perform more than one modification prior to SCNT (1-
gene targeting, 2-excise selectable marker).  Four of the six recipients became pregnant 
and the piglets were delivered by cesarean section (c-section) at day 116 of gestation, 
with the exception of 1 pregnancy that was terminated by c-section at gestation day 137.  
Of the four pregnancies, two pregnancies each contained a single piglet for a total of two 
live piglets (Figure 15).  The other two pregnancies resulted in 3 stillborn piglets (Table 
10).  The two live piglets, male: 6-1 and female: 11-1, were confirmed to contain the 
transgene cargo at the GGTA1 locus (Figure 15).  As mentioned above, the cells used 
were transiently transfected with the Cre recombinase, and both piglets had undergone 
some form of Cre-mediated excision of either one (6-1) or both selectable markers 
excised (11-1) (Figure 15).  Piglet 11-1 was null at the GGTA1 locus, this was due to one 
allele being targeted by the targeting vector and the other allele was modified by NHEJ.  
Piglet 11-1 died one-hour post c-section and piglet 6-1 was euthanized at 14 days of age.  
Tissues from both piglets were collected for further analysis of transgene expression. 
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Table 9. Cloned fetus produced following SCNT on gene-stacked cells. 
 
Nuclear 
Transfer 
Number of Reconstructed 
Embryos Transferred 
Surrogate 
Number Outcome 
Number 
Born Alive 
Additional 
Comments 
NT1 199 O049 Return N/A N/A 
NT2 193 W200853 Open N/A N/A 
NT3 188 W200852 Pregnant 0 1 day 45 fetus collected 
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Table 10. Cloned piglets produced following SCNT on gene-targeted cells. 
 
Nuclear 
Transfer 
Number of Reconstructed 
Embryos Transferred 
Surrogate 
Number Outcome 
Number 
Born Alive 
Additional 
Comments 
NT1 222 O231 Pregnant 0 1 stillborn delivered 
NT2 144 O204 Pregnant 1 Euthanized: Age 14 days 
NT3 214 O244 Return N/A N/A 
NT4 210 O240 Pregnant 1 Died:  Age 1 hour  
NT5 208 W200077 Pregnant 0 
2 stillborn 
piglets; day 
137 c-section 
NT6 163 O344 Return N/A N/A 
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Figure 14.   GGTA1IRES-Neo; PGK-Hygro; CAG-hCD55; Tie2-hCD39/+ Pigs.   
A) Image of piglet 6-1 at 10 days of age, born August 11, 2014.   
B) Graphical representation of the Upstream PCR Assay.  The top image is a 
representation of the PCR product at a pBB57-targeted allele.  The following images are 
representations of the PCR product if one of the three possible cre-mediated excision 
events occurred.  
C) Genotyping of pigs.  For genotyping, a PCR was performed to verify gene targeting 
by an upstream, long range, and downstream PCR.  PCR results from piglets 6-1 and 11-
1 demonstrate that one allele is targeted.  In piglet 11-1, the second allele was confirmed 
to have a major deletion in the GGTA1 locus, thus this animal is homozygous KO for 
GGTA1, but hemizygous for hCD39 and hCD55.  Long Range (Lanes 3 – 8) and 
Upstream Assay (Lanes 9 – 14) – Lane 1: DNA Ladder, Lambda Genome digested with 
BstEII, Lane 2: empty lane, Lanes 3 and 9: Piglet 11-1, Lanes 4 and 10: H2O negative 
control, Lanes 5 and 11: Wild-type control, Lanes 6 and 12: pBB18 targeted positive 
control, Lanes 7 and 13: Piglet 6-1, Lanes 8 and 14: positive control pBB57 fetus.  
Downstream Assay – Lane 1: DNA Ladder, Lambda Genome digested with BstEII, Lane 
2: H2O negative control, Lane 3: Piglet 6-1, Lane 4: Piglet 11-1, Lane 5: Wild-type 
control. 
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Transcript Expression of hCD39 in GGTA1 Targeted Pig Tissues 
Human CD39 mRNA expression, as determined by PCR of cDNA, was evident in 
all tissues examined in transgenic animals (Figure 16).  The controls (wild-type pig 
cDNA, no template control, and transgenic animal tail DNA) demonstrated that samples 
were appropriately negative for the presence/contamination of genomic DNA for both 
human CD39 and swine GAPDH. 
 
Immunohistochemistry – Cell Surface Expression of hCD39 and hCD55 in GGTA1 
Targeted Pig Organs 
 As expected, negative control images of both tail and umbilical did not show 
staining for either human CD39 or human CD55 (Figure 17 A, B, E, and F).  Fixed 
tissues from piglet 6-1 and 11-1 displayed robust-ubiquitous human CD55 expression 
that was associated with cell membranes (images of tissues from animal 11-1 are shown 
in Figure 17: C, D, G, H, I, J, K, L, M, N, O, P).  In addition, fixed tissues from piglet 11-
1 displayed endothelial-specific expression for human CD39 and all other cell types did 
not appear to express CD39.  Together with the result of transcription for human CD39 
expression, these results demonstrate that the transgenes are properly expressed in the 
desired cell type. 
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Figure 15.   Reverse Transcriptase PCR Analysis of Tie2-hCD39 Transgene 
Expression.   
A) Graphical representation of the location of the PCR.  Predicted size of PCR product 
for both genomic DNA and processed RNA after splicing of engineered intron.   
B) Primers are specific to 5'UTR of Tie2 promoter sequence and hCD39 and show non-
cross reactivity with wild-type porcine cDNA.  Piglets 6-1 and 11-1 were determined to 
express the Tie2-hCD39 transgene in all tissues examined.  Lane 1: DNA Ladder, pBR 
digested with MspI (NEB), Lane 2: Transgenic 6-1 Heart cDNA, Lane 3: Transgenic 6-1 
Liver cDNA, Lane 4: Transgenic 6-1 Lung cDNA, Lane 5: Transgenic 6-1 Kidney cDNA, 
Lane 6: Transgenic 6-1 Pancreas cDNA, Lane 7: Transgenic 6-1 Spleen cDNA, Lane 8: 
Wild-type Liver cDNA, Lane 9: Wild-type Lung cDNA, Lane 10: Wild-type Kidney 
cDNA, Lane 11: Wild-type Pancreas cDNA, Lane 12: Wild-type Heart cDNA, Lane 13: 
H2O negative control, and Lane 14: Transgenic 6-1 Genomic DNA. 
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Figure 16.  Representative immunohistochemistry analysis of human CD55 and 
human CD39 expression. 
Immunohistochemistry of wild-type pig tail and umbilical (used as a negative control); 
transgenic GGTA1CAG-hCD55; Tie2-hCD39/+ pig (11-1) heart, kidney, liver, lung, pancreas, tail, 
and umbilical tissues were stained against an anti-Human CD55 antibody and an anti-
Human CD39 antibody.  Panel A, B, C, and D: Tail Tissue; Panel E, F, G, and H: 
Umbilical Tissue; Panel I and J: Liver Tissue; Panel K and L: Heart Tissue; Panel M and 
N: Pancreas Tissue; Panel O and P: Kidney Tissue.  The transgenic (GGTA1CAG-hCD55; Tie2-
hCD39/+) pig shows diffuse-ubiquitous human CD55 expression and endothelial specific 
expression of human CD39 on all transgenic tissues with no expression on wild-type 
tissues. 
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Discussion 
Recent advances in genetic engineering technologies, including ZFNs, TALENs, 
and the CRISPR/Cas9 system, enable precise gene targeting including gene KO and 
targeted insertion in several organisms, including the pig (Whitworth et al., 2014; Zhou et 
al., 2015).  Through two novel genetic engineering strategies, we have shown that it is 
possible to efficiently link multiple genes/modifications (NeoR cassette, HygroR cassette, 
hCD39, hCD55, and GGTA1 KO) by sequentially stacking additional transgenes into a 
previously targeted allele, as well as by targeted insertion of multiple transgenes (NeoR 
cassette, HygroR cassette, hCD39, and hCD55) into a single locus (GGTA1).  This 
strategy would guarantee the co-inheritance of multiple genetic modifications.   
We chose to take advantage of DNA repair mechanisms (i.e., HR by using a 
targeting vector) in conjunction with induced target breakage in the genome to facilitate 
an increase in HR.  As a proof-of-principle, we elected to evaluate transgene linking to a 
disrupted locus within the context of xenotransplantation.  In order for pig-to-human 
xenotransplantation to be successful, it has become evident amongst the 
xenotransplantation community that in addition to GGTA1 KO, additional transgenes 
involving suppression of human immune function are going to be required (Cooper et al., 
2002; Cooper et al., 2012).  In addition, the ability to have such transgenes genetically 
linked could be extremely useful in building a multi-transgenic xenotransplantation pig. 
To facilitate precise modifications, the use of HR has had a tremendous impact on 
genetic engineering strategies (Mansour et al., 1988; Capecchi, 1989; Hasty, Rivera-
Perez, & Bradley, 1991; Hasty & Bradley, 1993; Fiering et al., 1995; Smih et al., 1995; 
Nagy & Rossant, 1996; Whyte et al., 2011).  It was demonstrated 20 years ago that gene 
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targeting could be stimulated by a genomic DSB introduced by a restriction enzyme 
(Rouet et al., 1994; Smih et al., 1995).  More recently, the CRISPR/Cas9 system, a 
programmable RNA guided DNA endonuclease, has emerged as an easy-to-use and 
efficient method for inducing site-specific DNA cleavage (Jinek et al., 2012).  Due to the 
high efficiency of the CRISPR/Cas9 system and the enhancement of HR post target DSB, 
we wanted to evaluate the efficiency of gene targeting to stack additional transgenes next 
to previously targeted transgenes.   
Since experimental parameters have not been defined for CRISPR/Cas9-mediated 
gene targeting, we chose to evaluate the ratios of DNA (targeting vector DNA and 
CRISPR/Cas9 expression vector).  We were able to identify an effect in the ratio of 
targeting vector DNA to CRISPR/Cas9 expression vector DNA and that in the presence 
of more CRISPR/Cas9 expression vector DNA, the higher the gene targeting efficiency 
(Figure 13).  The average efficiencies of CRISPR/Cas9 to mediate targeted insertion of 
two additional transgenes increased from 8.7% (only targeting vector DNA) to 37.0% of 
the colonies screened.  Based upon the initial success of targeted insertion of two 
transgenes into a previously targeted allele, we chose to evaluate the efficiencies of 
inserting four transgenes into a targeted site through CRISPR/Cas9-mediated gene 
targeting (Figure 14).  We were able to demonstrate that the CRISPR/Cas9 system can 
efficiently target the porcine GGTA1 locus and insert four independent, functional 
transgenes.  The cells that contained all four modifications were used for SCNT and live 
pigs were generated to evaluate the expression of hCD39 and hCD55. 
The resulting pigs had ubiquitous, non-variegated expression of hCD55 transgene 
and endothelial cell-specific expression of hCD39.  hCD55 has been proposed as a key 
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transgene to inhibit the human complement cascade, thus combating hyper acute rejection 
(Cozzi et al., 1997; Diaz-Roman et al., 2006; Lee et al., 2011).  To aid in coagulation and 
blood clotting during transplants, an anti-thrombotic transgene would be useful.  CD39 is 
an important regulator of platelet function, and hCD39 transgenic mice have 
demonstrated impaired platelet aggregation and prolonged bleeding times (Dwyer et al., 
2004). This antithrombotic phenotype would be valuable for the prevention of 
undesirable coagulation and blood clotting during transplants.  It should also be noted, 
that both hCD55 and hCD39 expression was comparable in all tissues examined.   
Work performed by several groups has shown the murine ROSA26 locus to be a 
safe harbor for generalized transgene expression (Friedrich & Soriano, 1991; Soriano, 
1999; Awatramani et al., 2001).  Based upon the given results of the proper expression of 
multiple transgenes and previous demonstration that GGTA1 null pigs are normal (Phelps 
et al., 2003; Kolber-Simonds et al., 2004; Takahagi et al., 2005), we propose that the 
porcine GGTA1 locus is a safe-harbor in the porcine genome for transgenes. 
In summary, gene targeted (both gene stacked and gene targeting) pigs can be 
efficiently produced by using the CRISPR/Cas9 system with a targeting vector.  This 
gene-targeting strategy provides a convenient and efficient approach to generate 
genetically engineered pigs, yet easily applicable to other species.  In regards to 
xenotransplantation, our study showed that multiple genes with various gene expression 
patterns could be expressed appropriately, while remaining genetically linked together.  
Future work would include the production of homozygous GGTA1 KO pigs that would 
contain two copies of both hCD39 and hCD55 (one copy on each targeted allele).  Once 
	   124 
these pigs are generated, further characterization and potential xeno-related utility of the 
multi-transgenic xeno-pig would need to be evaluated.  
	   125 
 
 
CHAPTER V 
 
 
SUMMARY AND CONCLUSIONS 
 
 
The ability to precisely modify the genome has and will continue to have 
profound effects in the fields of agriculture and human medicine.  The current protocols 
used are effective, but additional enhancements in the efficiencies are desirable.  In 
particular, any added efficiency to modify the genomes in livestock species will have a 
profound impact.  This is due in large part to the expenses related to husbandry of large 
animals in comparison to that of small animals.  The aim of this dissertation was to 
develop an efficient system to precisely modify the pig genome and to develop a system 
that would link multiple modifications, either gene KO or the addition of transgenes.  
There were three main topics that were evaluated: 1) Phic31 system in pigs, 2) effect of 
donor DNA length in nuclease-mediated gene targeting, and 3) CRISPR/Cas9-mediated 
gene stacking and gene targeting. 
Due to the success of the PhiC31 system in other species, we initially evaluated 
the PhiC31 system as an efficient method to sequentially add and/or stack transgenes in 
the pig.  We were able to demonstrate that, upon optimization, transient PhiC31 
expression is possible in pig cells.  We additionally demonstrated that PhiC31-mediated 
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gene stacking is possible with small (5.0 kb) and large (19.7 kb) attP vectors.  However, 
the efficiencies were not as predicted based upon results in other species.  The rate of 
stable PhiC31-mediated integrations ranged from 1.3 – 5.0% of evaluated colonies.  
These efficiencies are comparable to current gene targeting efficiencies.  Thus we chose 
to investigate nuclease-mediated gene targeting. 
In gene targeting, it is known that a genomic DSB is a rate-limiting factor.  
Customized nucleases provide a means to generate DSB at specific locations to a genome, 
thereby increasing the efficiency of gene targeting.  Even though these nucleases are 
currently used in genetic engineering strategies, the standards for donor DNA design in 
conjunction with the nucleases have not yet been established.  Therefore we wanted to 
evaluate the effect of donor DNA length on nuclease-mediated gene targeting.  We 
described the disruption of two genes (CMAH and GGTA1) through ZFN- and TALEN-
mediated gene targeting in pigs, respectively.  As a proof of principle, in vitro we used 
ZFNs and determined that a minimum homologous arm length of 35 bp will induce HR.  
In subsequent experiments to determine the minimum length of homology, we used 
TALEN-mediated gene targeting.  Based upon our ZFN/CMAH observations, we 
expected to see gene targeting at some frequency in our TALEN/GGTA1 experiments.  
Unexpectedly, we did not observe any gene targeting by HR with donor DNA, but 
instead demonstrated that the addition of donor DNA increases bi-allelic modifications 
when compared to TALEN-mediated editing in the absence of donor DNA.   
Given the recent success of the CRISPR/Cas9 system and its ability to create 
genomic DSB, we wanted to evaluate its ability to stack multiple transgenes into a 
predetermined location through gene targeting.  In summary, gene-targeted (both gene 
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stacked and gene targeting) pigs can efficiently be produced by using the CRISPR/Cas9 
system with a targeting vector.  Overall, we demonstrated that efficiencies can increase 
from ~5% in the presence of donor DNA, up to ~50% by using the CRISPR/Cas9 system 
in the presence of donor DNA.  This gene-targeting strategy provides a convenient and 
efficient approach to generate genetically engineered pigs.  In regards to 
xenotransplantation, our study showed that multiple genes with various gene expression 
patterns could be expressed appropriately, while remaining genetically linked together.  
Future work would include the production of homozygous GGTA1 KO pigs that would 
contain two copies of both hCD39 and hCD55 (one copy on each targeted allele).  Once 
these pigs are generated, further characterization and potential xeno-related utility of the 
multi-transgenic xeno-pig would need to be evaluated.   
In conclusion, we have demonstrated several methods to manipulate the swine 
genome and the collective data described within this dissertation could affect the 
strategies researchers use to implement their genetic engineering schemes.  
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